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ABSTRACT
MECHANISM OF CYCLIN D1-DEPENDENT GENOMIC INSTABILITY AND
NEOPLASTIC TRANSFORMATION
Laura Pontano Vaites
Dr. J. Alan Diehl
Regulation of cyclin D1-dependent kinase activity is essential for cell cycle progression
and DNA replication fidelity. Critically, impaired cyclin D1 phosphorylation and
ubiquitin-mediated proteolysis following the G1/S transition drives neoplastic growth,
suggesting that posttranslational regulation is required for cell homeostasis. Elucidation
of mechanisms facilitating S-phase cyclin D1 accumulation and novel functions of
nuclear cyclin D1/CDK4 kinase is critical for understanding the role of cyclin D1 in
tumorigenesis. The work presented herein demonstrates that accelerated, Fbx4-dependent
cyclin D1 degradation following S-phase DNA damage is essential to maintain genome
stability. Furthermore, Fbx4 functions as a bona fide tumor suppressor, as Fbx4-deficient
mice develop spontaneous tumors and murine fibroblasts exhibit cyclin D1 stabilization,
nuclear accumulation, and associated genomic instability. This work also describes novel
regulation of the PRMT5 methyltransferase by nuclear cyclin D1/CDK4, thereby
facilitating histone methylation and gene repression during S-phase necessary for
neoplastic growth. Finally, current work reveals a synergistic relationship between
constitutively nuclear cyclin D1 and impaired DNA damage checkpoint integrity in
driving lymphomagenesis in mice. Collectively, these findings define an intricate
relationship wherein nuclear cyclin D1/CDK4 activity modulates genetic alterations
necessary for perturbed DNA replication, genomic instability, and ultimately neoplasia.
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CHAPTER I:
INTRODUCTION

The sections entitled
“Insights into cyclin D1 overexpression and nuclear accumulation”
and
“Constitutively nuclear cyclin D1 drives genomic instability”
have been published in part (including Figure 1.4/Table 1) in:

Pontano L.L. and Diehl J.A. (2008).
Speeding through cell cycle roadblocks:
Nuclear cyclin D1-dependent kinase and neoplastic transformation.
Cell Division 3 (12).
(Pontano and Diehl, 2008)
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Cell cycle progression is intricately controlled by coordinated expression and
ubiquitin-dependent degradation of key regulatory proteins. Temporally expressed
mammalian cyclins serve as allosteric activators of cyclin dependent kinases (CDKs);
active cyclin/CDK complexes catalyze phosphorylation events necessary for S-phase
entry, DNA replication, and mitosis. CDK activity is regulated at each stage of the cell
cycle, as labile cyclin proteins are targeted for proteasomal degradation by E3 ubiquitin
ligases. The work presented herein focuses on mechanisms that control cell cycleregulated accumulation of cyclin D1. Mitogen-dependent cyclin D1 expression and
activation of CDK4 drives progression through G1 phase; critically, ubiquitin-mediated
cyclin D1 proteolysis antagonizes nuclear cyclin D1/CDK4 activity following the G1/S
transition. Cyclin D1 overexpression occurs frequently in human cancer and is thought to
be a driving factor in neoplastic transformation. Recent evidence suggests that impaired
protein degradation allows accumulation of active, nuclear cyclin D1/CDK4 kinase
throughout the cell cycle; such aberrant nuclear cyclin D1/CDK4 activity in turn
modulates neoplastic effects. Here, I will review cell cycle regulation by CDKs and
ubiquitin ligases and discuss recent insights into cell cycle-dependent cyclin D1
regulation and mechanisms contributing to cyclin D1-driven tumorigenesis.

Temporal Cyclin/CDK activity drives cell proliferation.
The concerted activity of multiple mammalian CDKs coordinates cell cycle
progression, dependent on timely expression of corresponding activating cyclins and
subsequent threonine phosphorylation within the CDK T-loop by the CDK activatingkinase (CAK), consisting of CDK7/Cyclin H (Russo et al., 1996). While CAK activity is
2

thought to be constitutively active in eukaryotic cells, temporal CDK activation depends
upon cyclin binding, which facilitates structural changes in the CDK allowing enhanced
ATP catalysis (Jeffrey et al., 1995). The crystal structure of CDK2 alone, CDK2 in
complex with cyclin A, and the cyclin A/CDK2/p27KIP1 ternary complex, provided
valuable insight into the “molecular switch” function of CDK kinases in controlling cell
cycle progression. For instance, mitogen-dependent cyclin induction in G1 phase
coordinates growth signals with CDK activation. Alternatively, anti-proliferative signals
such as senescence and DNA damage checkpoint activation lead to induction of cyclin
dependent kinase inhibitors (CKIs) of the CIP/KIP and INK4 families, switching CDK
activity off (Pavletich, 1999).
A large body of work established specific cyclin/CDK partnerships (Figure 1.1):
G1-phase D-type cyclins and CDK4/6, S-phase cyclins E/A and CDK2, and G2/M phase
cyclins A/B and CDK2/CDK1 (Aleem et al., 2005; Draetta et al., 1989; Sherr, 1994).
Typically, cyclin D/CDK4/6 kinase activity promotes G1 progression by phosphorylating
the retinoblastoma protein (Rb) and related pocket proteins p107/p130, relieving Rbdependent E2F inhibition. Cyclin E/CDK2 also phosphorylates Rb in late G1; cyclin E
mRNA levels rapidly increase at this time, and cyclin D/CDK4/6 complexes titrate the
CIP/KIP class of CKIs from cyclin E/CDK2 complexes, facilitating activation. Rb
hyperphosphorylation by site-specific, concerted CDK4 and CDK2 activity triggers
complete Rb dissociation from E2F and commits the cell to S-phase entry (ConnellCrowley et al., 1997; Harbour et al., 1999; Weinberg, 1995). At this stage, Rb
inactivation shifts from dependency upon mitogen signaling toward mitogen-independent
cyclin E/CDK2 activity. Consequently, nuclear cyclin D/CDK4/6 activity is terminated
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by degradation of D-type cyclins (Figure 1.2). While distinct mechanisms governing
cyclin D2 and D3 regulation are largely unknown, work over the past decade revealed
that cyclin D1 is targeted for proteasomal degradation via phosphorylation-dependent
nuclear export and cytoplasmic ubiquitylation (Diehl et al., 1998; Diehl et al., 1997).
As cells enter S-phase, CDK activity facilitates activation of replication origins
and prevention of origin re-loading. This contradictory function is achieved through
temporal CDK regulation; cyclin E/CDK2 activity in early S-phase triggers origin firing,
while cyclin A/CDK2-dependent inactivation of pre-RCs occurs in late S- and G2-phases
(Bell and Dutta, 2002). Early in S-phase, cyclin E is targeted for ubiquitin-mediated
proteolysis (Clurman et al., 1996). Conversely, cyclin A is expressed in late G1, with
maximal accumulation by late S/G2, where cyclin A/CDK2 activity regulates cell cycle
progression in several ways. First, cyclin A/CDK2 activity terminates E2F-dependent
gene transcription through phosphorylation of the DP-1 heterodimeric component of E2F
transcription factors, precluding DNA binding (Sherr, 1996). Second, cyclin A/CDK2
terminates pre-RC assembly by phosphorylating CDC6, triggering its nuclear export in
mammalian cells, and inhibiting MCM complex association with chromatin (Petersen et
al., 1999; Petersen et al., 2000). Finally, cyclin A/CDK2 phosphorylates CDT1, targeting
soluble CDT1 for SCFSKP2-dependent ubiquitylation. However, chromatin-bound CDT1 is
degraded in a phosphorylation-independent, PCNA- and DNA-dependent manner by
CUL4CDT2 (Havens and Walter, 2009; Nishitani et al., 2006; Vaziri et al., 2003).
In addition to S-phase functions, cyclin A/CDK2 regulates centrosome
duplication and CDC25 phosphorylation in G2, and impaired cyclin A/CDK2 activity
delays subsequent cyclin B/CDK1 activation (Baldin et al., 1997; De Boer et al., 2008;
4

Meraldi et al., 1999). CDK1 activation requires dephosphorylation of T14 and Y15 at the
G2/M boundary, when CDC25 dual specificity phosphatase activity exceeds inhibitory
Wee1/Myt1-dependent CDK phosphorylation (Nigg, 2001). However, cyclin B/CDK1 is
initially sequestered in the cytoplasm during S-phase and early G2, preventing pre-mature
mitotic entry, followed by nuclear localization upon nuclear lamina breakdown at the
G2/M transition (Pines and Hunter, 1991). Cyclin B phosphorylation within its
cytoplasmic retention sequence is thought to facilitate nuclear accumulation. Although
the distinct mechanism governing cyclin B/CDK1 nuclear entry remains elusive, recent
work supports a role for coupling cyclin B1/CDK1 cytoplasmic activation to rapid
nuclear import (Gavet and Pines; Yang et al., 1998). Cyclin B/CDK1 phosphorylates a
plethora of substrates including the cytoskeleton, nuclear lamins, nucleolus, nuclear pore
complexes, and the APC/C, leading to APC/C activation and cyclin destruction required
for mitosis (Kraft et al., 2003). Clearly, cells have evolved intricate regulatory networks
built upon post-translational modification of cyclins, CDKs, and inhibitory molecules
necessary for temporal CDK activity and tight control of cell proliferation.

Functional redundancy among cell cycle-driving cyclin/CDK complexes.
A current model of CDK activity suggests that differential function of
cyclin/CDK complexes is mainly controlled by spatiotemporal distribution during the cell
cycle and less dependent upon specificity toward individual substrates (Moore et al.,
2003). For instance, traditional models suggest that cyclin E/CDK2 functions in early Sphase, facilitating DNA replication, and cyclin A/CDK2 functions in late S-phase to
inhibit origin relicensing. However, cyclin A/CDK2 can drive DNA replication in the
5

absence of cyclin E, suggesting functional redundancy between these kinases (Rosenberg
et al., 1995; Strausfeld et al., 1996). Furthermore, the idea that specific CDKs drive a
single cell cycle event has been challenged by genetic studies, providing insight into the
requirement for specific and redundant cyclin/CDK function during development.
Genetic ablation of G1 CDKs revealed that mice develop beyond embryogenesis,
with phenotypes observed in differentiated cells. CDK4-deficient mice are small and
infertile; however, these mice develop diabetes, suggesting a requirement for CDK4 in cell proliferation. Conversely, overexpression of a p16INK4A-refractory R24C CDK4 allele
drives pancreatic hyperplasia, highlighting the importance for CDK regulation in this
tissue (Rane et al., 1999). CDK4-deficient murine embryonic fibroblasts (MEFs) cycle
normally under growth-stimulating conditions, yet quiescent cells exhibit a substantial Sphase entry delay, which is rescued by loss of p27. Compound deletion of CDK4 and
CDK6 is embryonic lethal, as embryos exhibit severe anemia due to hematopoietic
proliferative defects. These findings signify the importance of CDK4-dependent
sequestration of p27, contributing to cyclin E activation (Malumbres et al., 2004; Tsutsui
et al., 1999). Finally, CDK2 is required for meiotic cell division, but is dispensable in
cycling mitotic cells, suggesting redundancy with CDK1 function (Ortega et al., 2003).
While CDK4 and CDK2 deletion independently results in normal embryogenesis,
compound loss of both CDKs is embryonic lethal due to heart defects, and MEFs exhibit
reduced Rb phosphorylation and E2F gene activation, consistent with impaired S-phase
entry (Berthet et al., 2006). In contrast, mice lacking both CDK6 and CDK2 develop
normally, with phenotypic abnormalities consistent with each individual knockout
(Malumbres et al., 2004). Given these findings, it is quite interesting that exclusive
6

expression of CDK1 is sufficient for mammalian cell cycle progression. Mice expressing
CDK1 alone develop to mid-gestation, and MEFs proliferate in culture, despite prolonged
cycle duration associated with inefficient Rb inactivation. CDK1 ablation results in
embryonic lethality prior to the morula stage, suggesting that CDK1 can drive all cell
cycle transition events required for cell division and early embryonic development
(Santamaria et al., 2007). Further supporting this notion, knocking in CDK2 at the
endogenous CDK1 locus failed to rescue CDK1 deficiency (Satyanarayana et al., 2008).
Similar to genetic CDK models, various individual and combinatorial cyclin
knockouts revealed significant redundancy in cell cycle regulation. Knockout mouse
models of each respective D-type cyclin demonstrated that mice develop normally,
without severe proliferative defects. However, each model exhibited moderate, tissue
specific defects, suggesting a non-redundant pattern of expression in various cell types.
Tissue-specific phenotypes in cyclin D1-deficient mice include small size, retinal
hypoplasia, neurological defects, and defective mammary gland development (Fantl et
al., 1995; Sicinski et al., 1995). In contrast, cyclin D2-null animals exhibit defects in Bcell proliferation, -cell proliferation, and cerebellar development, and cyclin D3-null
mice show impaired T-cell development (Huard et al., 1999; Kushner et al., 2005;
Sicinska et al., 2003; Solvason et al., 2000). Together, these findings established a
context-dependent role for the D-type cyclins in driving cell proliferation.
Mice expressing a single D-type cyclin or lacking all three cyclins survive to midstages of embryogenesis. Mice lacking cyclin D1/D2 survive postnatally, exhibiting
phenotypes consistent with each respective knockout. However, loss of cyclin D1/D3 and
cyclin D2/D3 is lethal postnatally or in late embryogenesis due to neurological defects
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and severe anemia, respectively, suggesting that a single D-type cyclin is insufficient for
tissue maturation and adult development (Ciemerych et al., 2002; Kozar et al., 2004).
Consistent with the D-type cyclins, individual deletion of cyclin E1 or E2 does not impair
viability or development, yet compound deletion results in embryonic lethality due to
placental defects. Double knockout MEFs exhibit delayed S-phase progression, but both
cyclin D/A can compensate for cyclin E function at the G1/S transition (Geng et al.,
2003; Parisi et al., 2003). Additionally, loss of ubiquitously expressed cyclin A2 results
in mortality after implantation (Murphy et al., 1997). Recent development of cyclin A2
conditional knockout mice revealed that this cyclin is essential for hematopoietic and
embryonic stem cell proliferation (Kalaszczynska et al., 2009), supporting a nonredundant function that cannot be compensated by cyclin E/B. Finally, ablation of cyclin
B1 results in embryonic lethality, while loss of cyclin B2 has no gross effects, suggesting
redundancy among these cyclins, but a requisite role for cyclin B1 in mitotic function
(Brandeis et al., 1998).
Genetic cyclin/CDK manipulation in vivo provided novel insight into how these
kinases can be exploited to modulate cell cycle progression. Importantly, deregulation of
G1 and S-phase CDKs and respective CKIs has been implicated in the genesis of human
cancer. CDK4 overexpression due to gene amplification and less commonly mutation has
been well documented, and loss or silencing of the INK4 locus occurs in a vast array of
tumors (Sherr, 1996). Furthermore, cyclin D1 is frequently targeted in human cancer,
driving tumorigenesis through activation of CDK4. For instance, knock-in mice
harboring cyclin D1K112E (replacement of lysine with glutamic acid) alleles exhibit
similar neurological defects and small size observed in cyclin D1-/- mice, and more
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importantly, these mice are refractory to Neu-mediated mammary tumorigenesis. Cyclin
D1K112E binds CDK4 and p27KIP1 with normal affinity, but cannot facilitate CDK
activation (Landis et al., 2006). Interestingly, retinal and mammary gland development is
unaltered in cyclin D1K112E mice, consistent with evidence suggesting that p27 is epistatic
to cyclin D1 in these tissues (Geng et al., 2001; Landis et al., 2006). Additionally,
overexpression of cyclin E occurs frequently in cancer, implicating the cyclin E/CDK2
kinase in cell cycle deregulation as well (Hwang and Clurman, 2005). Collectively, the
large body of work describing CDK deregulation in cancer suggests that alteration of a
single cyclin/CDK module is sufficient to promote aberrant cell growth, and subsequent
loss of checkpoint constraints facilitates neoplastic transformation.
Given the neoplastic effects of sustained CDK activity, it is not surprising that
cells harbor multiple mechanisms to keep CDK activity in check. Intricate checkpoint
mechanisms limit CDK activity following genotoxic insult and various other stresses,
including induction of CKIs such as p21CIP1, degradation of cyclins, and inactivation of
CDC25 phosphatases required for CDK activation. Following DNA damage, members of
the PI(3)K (phosphatidylinositol-3-OH kinase)-like kinase (PIKK) family respond to
double strand breaks (DSBs) and single strand DNA (ssDNA) and signal directly and
through effector kinases, triggering p53 stabilization and p21CIP1 induction (Kastan and
Bartek, 2004). These signals induce rapid cell cycle arrest in G1 phase. In S-phase and
G2, signaling through PIKKs and downstream effectors also mediates phosphorylation of
the CDC25 phosphatases; phosphorylated CDC25A is targeted for degradation by the
SCF-TrCP E3 ubiquitin ligase, and CDC25B/C phosphorylation promotes 14-3-3 binding
and nuclear exclusion. Additionally, the DNA damage effector kinase CHK1 activates
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WEE1, the kinase responsible for inhibitory phosphorylation on CDK2 and CDK1
(Reinhardt and Yaffe, 2009). Ultimately, tightly controlled CDK activity is achieved by
coupling signaling events with E3 ubiquitin ligase function to maintain cell homeostasis.

E3 ubiquitin ligases control accumulation of cell cycle regulatory proteins.
Cell cycle progression is driven by alternating phases of cyclin accumulation and
destruction via the ubiquitin-proteasome machinery, respectively (Evans et al., 1983;
Glotzer et al., 1991). Ubiquitylation of target substrates requires the concerted activity of
an ubiquitin activating enzyme (E1), ubiquitin conjugating enzyme (E2), and ubiquitin
ligase (E3). Although certain E3 ligases, such as the HECT-domain family, directly
transfer ubiquitin, many E3 ligases function as multi-subunit complexes that bridge the
ubiquitin charged E2 enzyme with a given substrate protein (Ciechanover, 1994; Hershko
and Ciechanover, 1998). Covalent, posttranslational ubiquitin linkages serve many
cellular functions including proteasomal targeting, signaling, endocytosis, and protein
interactions. Importantly, lysine-48 polyubiquitin conjugation targets substrate molecules
for proteasomal degradation (Winget and Mayor).
Biphasic activity of two major E3 ligases, the SKP1-CUL1-F-Box (SCF) family
and the anaphase promoting complex/cyclosome (APC/C), controls temporal cell cycle
progression by targeting cyclins, CKIs, and other cell cycle regulators for proteasomal
degradation. The SCF family of E3 ubiquitin ligases promotes polyubiquitylation of
mainly phosphorylated substrates, including key regulators of G1 progression (Skowyra
et al., 1997). The core cullin subunit, CUL1, functions as a scaffold for the RING-domain
protein RBX1, required for E2 recruitment, and the adapter protein SKP1, required for
10

substrate receptor recruitment. The SKP1 adapter associates with a given F-box protein,
the specificity factor for substrate recognition (Figure 1.3A); over 70 F-boxes have been
described in human cells, making the diversity of substrate recognition by SCF ligases
quite vast (Petroski and Deshaies, 2005). SCF ligases function throughout the cell cycle
and are regulated by cullin neddylation; this modification structurally alters the cterminal RING binding domain of the cullin, increasing the processivity of ubiquitin
transfer from the E2 to the substrate (Saha and Deshaies, 2008). The APC/C, on the other
hand, is a modular ligase that promotes substrate degradation at the G2/M and M/G1
transitions. The APC/C consists of the APC11 RING domain protein, APC2 cullin
homolog, two activating subunits, CDC20 and CDH1, and various scaffolding subunits
(Harper et al., 2002; Petroski and Deshaies, 2005).
Ubiquitin-mediated destruction of inhibitory proteins ensures timely cell cycle
progression; similarly, ubiquitylation and degradation of cyclins provides restrictive
control necessary for DNA replication fidelity and mitosis. The APC/C coordinates
mitotic progression and establishment of the next ensuing cell cycle by employing two
respective substrate recognition adapters, CDC20 and CDH1. APC/CCDC20 controls the
G2/M transition, degrading mitotic substrates such as cyclin A, cyclin B, and securin
(Peters, 2006; Yu, 2007). APC/CCDH1 also assists APC/CCDC20 with mitotic exit, but
functions mainly in G0/G1, targeting substrates including the CDK activator CDC25A,
F-box protein Skp2, and components of the DNA replication machinery for degradation,
thereby preventing premature cell cycle re-initiation (Manchado et al.). CDC20 and
CDH1 recognize distinct domains within substrates called destruction box domains (Dbox, amino acid sequence R-X-X-L-X-X-X-X-N), and CDH1 binds both D-box and KEN
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box domains (amino acid sequence K-E-N-X-X-X-E/D/N). This differential substrate
recognition pattern is important as cells exit mitosis, since CDC20 levels decline due to
recognition of its KEN box by APC/CCDH1 (Pfleger and Kirschner, 2000). While
APC/CCDH1 regulates mitotic activity of APC/CCDC20, mitogen-dependent CDK activity in
G1 promotes CDH1 phosphorylation and inactivation, and S-phase induction of the
APC/C inhibitor EMI1 prevents premature degradation of APC/C substrates (Miller et
al., 2006; Sorensen et al., 2001).
As APC/C activity decreases in G1, CDK activity increases, promoting
replication licensing and E2F-dependent gene transcription (Figure 1.2). At this time,
SCF E3 ligases come into play as cell cycle regulators, with F-boxes directing substrate
recognition. F-box adapters are classified by conserved structural motifs that facilitate
substrate binding. The “Fbw” class harbors WD40-repeat domains, the “Fbl” class
harbors leucine-rich repeats, and the “Fbx” class lacks these aforementioned domains
(Cenciarelli et al., 1999). Several SCF-like E3 ligases also control accumulation of cell
cycle regulatory proteins. The CUL7-based ligase shares structural similarity with
canonical SCFs, since it contains RBX1, SKP1, and Fbw8 (Figure 1.3B). This ligase has
been implicated in insulin receptor substrate-1 degradation, and previous work suggested
a role for SCFFbw8 and CUL7-Fbw8 ligases in cyclin D1 degradation (Okabe et al., 2006;
Xu et al., 2008). A second SCF-like E3 ligase consists of the cullin scaffold CUL4,
RBX1, DDB1 adapter, and various DDB1- and CUL4-associated factors (DCAFs), which
serve as substrate-specific receptors (Figure 1.3B, C). Similar to the “FBW” class of Fbox proteins, DCAF substrate recognition is achieved through substrate binding to WD40
repeats in the DCAF. The CUL4 ligase regulates multiple signaling pathways, including
12

DNA replication, repair, and transcription; importantly, CUL4CDT2 prevents DNA rereplication by targeting CDT1 for degradation (O'Connell and Harper, 2007).
As cells proceed into G1, D-type cyclin expression drives CDK activation
necessary for G1 progression. As described previously, cyclin D1/CDK4 kinase activity
is not necessary following the G1/S transition; recent work revealed that SCFFbx4 targets
phosphorylated cyclin D1 for proteasomal degradation. Cyclin D1 recognition requires
Fbx4 in concert with the co-factor B crystallin, a function analogous with the F-box
protein Skp2 and co-factor Cks1, which target the CKI p27KIP1 for degradation (Figure
1.2) (Lin et al., 2006). Similar to Fbw7, an ubiquitin ligase for cyclin E, c-Myc, and
Notch (Tang et al., 2007; Zhang and Koepp, 2006) and -TrCP, an E3 ligase for IB
(Suzuki et al., 2000), Fbx4 undergoes dimerization; however, in contrast to either Fbw7
or -TrCP, Fbx4 dimerization occurs in a cell cycle-dependent manner, and requires
GSK3-dependent phosphorylation at serine 12, which creates a 14-3-3 consensus site.
14-3-3 binding facilitates Fbx4 dimerizaton and ligase activation (Figure 1.2B) (Barbash
et al.; Barbash et al., 2008). In contrast to other well-characterized F-box proteins, Fbx4
recognizes both phosphorylated and non-phosphorylated substrates, cyclin D1 and TRF1,
respectively, and recent crystallographic evidence revealed that substrate binding occurs
within a non-characteristic GTPase-like domain within its c-terminus (Zeng et al., 2010).
While SCF activity switches cyclin D1/CDK4 activity off following the G1/S
transition, it turns on CDK2 and CDK1 activity in S- and G2-phase by regulating CKI
accumulation. SCFSkp2 targets p27KIP1 and p21CIP1 for proteasomal degradation; p27
phosphorylation on T187 by CDKs facilitates recognition by this E3 ligase (Bornstein et
al., 2003; Carrano et al., 1999; Tsvetkov et al., 1999). As cells begin DNA replication,
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cyclin E/CDK2 activity is no longer essential, and like cyclin D1, phosphorylated cyclin
E is targeted for proteasomal degradation. Initial studies suggested that CDK2-dependent
phosphorylation of T380 triggered cyclin E recognition by Fbw7, and subsequent work
revealed that concerted GSK3-dependent phosphorylation of T380 and CDK2dependent phosphorylation of S384 creates a phosphodegron motif that targets cyclin E
for Fbw7-mediated degradation (Koepp et al., 2001; Welcker et al., 2003). More recently,
biochemical analysis of the Fbw7 substrate-binding domain revealed critical arginine
residues within the WD40 repeats that facilitate formation of the phosphodegron-binding
pocket, and a dimerization domain proximal to the F-box facilitates Fbw7 dimerization,
increasing the processivity of substrate ubiquitylation (Hao et al., 2007; Welcker et al.).
Although the remaining S- and G2/M phase cyclins are APC/C substrates, SCF
ligases control CDK2 and CDK1 activity in response to various cellular cues. SCF-TrCP
functions as an integrator of signaling pathways and tightly controls CDK function. TrCP-dependent degradation of CDC25A following DNA damage prevents CDK2
activity until the checkpoint is resolved (Busino et al., 2003; Jin et al., 2003). -TrCP also
negatively regulates CDK activity by targeting the APC/C inhibitor EMI1 for degradation
in mitosis, leading to APC/C-mediated cyclin degradation (Guardavaccaro et al., 2003;
Margottin-Goguet et al., 2003). In contrast, -TrCP facilitates mitotic CDK activation by
targeting the CDK inhibitory kinase WEE1 for degradation, and -TrCP promotes CDK
activation upon termination of checkpoint signaling by degrading the checkpoint
mediator Claspin (Mailand et al., 2006; Peschiaroli et al., 2006; Watanabe et al., 2005;
Watanabe et al., 2004). Like Fbw7, -TrCP recognizes conserved phosphodegron motifs
(DpSGXXpS) containing two phosphorylated serine residues. -TrCP also undergoes
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dimerization, likely increasing ligase activity (Tang et al., 2007; Winston et al., 1999b).
In addition to regulating CDK activity, -TrCP integrates growth and stress signaling
with cell responses by targeting IB and -catenin for degradation, facilitating NFBdependent activation of inflammatory and pro-survival genes and antagonizing proproliferative Wnt signaling, respectively (Winston et al., 1999b).
While a large number of F-box proteins have been identified, few have been well
characterized (Fbw7, -TrCP, Skp2, and more recently Fbx4), highlighting the necessity
to elucidate substrates and pathways regulated by novel SCF ligases. Furthermore, it is
likely that most F-box proteins regulate multiple substrates, with recognition dictated by
structural determinants within the F-box protein, and/or posttranslational substrate
modifications. Given the complexity of SCF-mediated ubiquitylation in response to
various cell stimuli, it is likely that activities of multiple ligases can perform synergistic
or antagonistic functions regulating protein stability. This concept has been illustrated by
recent work suggesting that -TrCP-mediated c-Myc N-terminal ubiquitylation
antagonizes Fbw7-mediated c-Myc destruction (Popov et al., 2011). Furthermore, SCF
ligase function is an attractive target for deregulation during neoplastic transformation, as
accumulation of cell cycle drivers and survival proteins and downregulation of CKIs and
pro-apoptotic proteins provide a growth and survival advantage for tumor cells.

Deregulation of SCF E3 ligase activity promotes neoplastic transformation.
Considering that SCF ligases control accumulation of both oncogenes and tumor
suppressor proteins, alterations in ligase activity can elicit detrimental consequences for
the cell. Unrestricted SCFSkp2 activity, for example, is oncogenic, since this ligase targets
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tumor suppressor proteins such as p27KIP1 and FOXO1 for degradation (Carrano et al.,
1999; Huang et al., 2005). Interestingly, it has been proposed that Skp2 mediates cyclin
D1 degradation (Yu et al., 1998); however, direct ubiquitylation has not been
demonstrated (Nakayama et al., 2000). A likely explanation for cyclin D1 accumulation
in Skp2-/- cells is that stabilization of the Skp2 substrate p27 enhances cyclin D1 stability
as ternary cyclin D1/CDK4/p27 complexes are formed. Additionally, Skp2-/-; p27-/- mice
overcome phenotypes associated with Skp2 deficiency alone, suggesting that p27 is the
critical substrate of this ligase (Kossatz et al., 2004). Consistent with this notion, mice
lacking p27 display organ hyperplasia and develop pituitary tumors, and p27 is
haploinsufficient for tumor suppression (Fero et al., 1998; Fero et al., 1996; Nakayama et
al., 1996). Furthermore, other Skp2 substrates have alternative means of degradation; for
example, p21 is degraded by APC/CCDC20, and chromatin-bound CDT1 is degraded by
CUL4CDT2 (Amador et al., 2007; Nishitani et al., 2006).
Similar to SCFSkp2, SCF-TrCP targets tumor suppressor proteins for degradation,
including IB and PDCD4, a protein translation inhibitory protein (Dorrello et al., 2006;
Winston et al., 1999b). Aberrant IB degradation facilitates unrestricted NFBdependent transcription of inflammatory proteins, pro-survival factors, signaling
receptors, and adhesion molecules that promote tumor initiation and progression, and
NFB activation is a hallmark of inflammation-associated tumors (Karin and Greten,
2005). Similarly, PDCD4 restricts cell growth and survival by inhibiting the translation
factor eIF4A. PDCD4 is typically degraded in response to mTOR activation and S6
kinase function, and importantly, loss of PDCD4 is thought to promote cell
transformation. PDCD4 protein levels are downregulated in hepatocellular carcinomas,
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and loss of PDCD4 is associated with poor prognosis in lung cancers (Chen et al., 2003;
Dorrello et al., 2006; Zhang et al., 2006). Increased -TrCP expression has been
documented in various cancers including colon cancer and melanoma, and many of these
tumors exhibit positive NFB-dependent gene expression signatures, correlating with TrCP-dependent inactivation of IB (Liu et al., 2007; Ougolkov et al., 2004).
Furthermore, genetic studies revealed that loss of -TrCP confers a hypoplastic
mammary gland phenotype, while transgenic -TrCP expression drives mammary
epithelial cell proliferation, with a significant fraction of mice developing mammary,
uterine, and ovarian carcinomas (Kudo et al., 2004).
In contrast to Skp2 and -TrCP, Fbw7 functions as a tumor suppressor, as it
controls accumulation of several cell cycle proteins and transcription factors deemed to
be oncogenic. It has been established that Fbw7 targets cyclin E for degradation, and
more recent work defined a large set of transcription factors as Fbw7 targets, including cMyc, Notch, c-Jun, and SREBP (Inuzuka et al.; Nateri et al., 2004; Oberg et al., 2001;
Sundqvist et al., 2005; Welcker and Clurman, 2008; Welcker et al., 2004). Mechanistic
analysis of Fbw7 deregulation in cancer revealed mutation of critical arginine residues
within the substrate phosphodegron binding pocket, as well as mutations in substrates
that preclude Fbw7 binding. For example, the c-Myc oncogene is commonly mutated in
the region surrounding T58 required for Fbw7 recognition in Burkitt lymphomas, leading
to increased stability and tumor formation (Gregory and Hann, 2000). Fbw7 was initially
thought to be a haploinsufficient tumor suppressor, given the frequency of hemizygous
mutations in various human cancers including T-ALL; however, genetic studies revealed
that Fbw7+/- mice develop normally, and deletion of one allele of Fbw7 in the lymphocyte
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compartment does not drive lymphomagenesis (Onoyama et al., 2007; Tetzlaff et al.,
2004). Subsequent work investigating the effects of Fbw7 mutation and dimerization
revealed that a majority of Fbw7 mutations confer dominant-negative character, thereby
limiting ligase function (Welcker and Clurman, 2008).
Similar to Fbw7, recent evidence suggests that Fbx4 is a tumor suppressor, as
hemizygous Fbx4 mutations in human cancer impair ligase activity and lead to aberrant
nuclear cyclin D1 accumulation (Barbash et al., 2008). Importantly, the frequent
incidence of N-terminal mutations that impair ligase dimerization and full activity hints at
the fact that Fbx4 could function as a haploinsufficient tumor suppressor. In the following
section, I will elaborate on these findings and discuss recent work elucidating oncogenic
properties of cyclin D1 when SCFFbx4-mediated degradation is disrupted.

Insights into cyclin D1 overexpression and nuclear accumulation in cancer.
As described previously, nuclear cyclin D1 accumulation is antagonized by
phosphorylation-dependent nuclear export and cytoplasmic degradation following the
G1/S transition. Cyclin D1 is rapidly phosphorylated by GSK3 on T286, triggering
CRM1-dependent nuclear export, and SCFFbx4-dependent proteasomal degradation (Diehl
et al., 1998; Lin et al., 2006). Activation of SCFFbx4 ligase activity at this time also
facilitates cyclin D1 destruction. Collectively, multiple levels of cyclin D1 regulation
including nuclear export, increased ubiquitylation capacity, and degradation ensure that
this cell cycle driver does not accumulate or re-enter the nucleus during S-phase, limiting
its oncogenic potential (Figure 1.2).
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Paradoxically, cyclin D1 overexpression is considered a causative factor in many
tumor types, yet overexpression of wild type cyclin D1 is insufficient to drive neoplastic
transformation. However, cyclin D1 mutants refractory to phosphorylation and
subsequent proteasomal degradation are acutely transforming in vitro and in vivo,
implying that compartmentalization of cyclin D1/CDK4 is essential for cell homeostasis
(Alt et al., 2000; Gladden et al., 2006). Cyclin D1 overexpression occurs in carcinomas of
the breast, esophagus, head and neck, and lung. In a majority of cases, alterations in gene
expression cannot account for overexpression, suggesting that impaired degradation
contributes to cyclin D1 stability.
Mutations that inhibit cyclin D1 T286 phosphorylation are rare, occurring to date
only in endometrial and esophageal cancer. Single-base substitutions changing P287 to a
serine or threonine residue in endometrial carcinoma correlates with overexpression of
cyclin D1 in the nucleus of neoplastic cells, and a 12-base pair in frame deletion of amino
acids 289-292 was reported with overexpression of cyclin D1 (Moreno-Bueno et al.,
2003). Subsequent analyses revealed that disruption of P287 abrogates GSK3-dependent
phosphorylation of T286, and deletion of residues 289-292 impairs cyclin D1 binding to
CRM1, both resulting in nuclear accumulation (Benzeno and Diehl, 2004; Benzeno et al.,
2006). In accordance with endometrial cancer, recently identified cyclin D1 mutations in
esophageal cancer and tumor-derived cell lines also disrupt T286 phosphorylation. Cyclin
D1 sequence analysis in a panel of 90 esophageal carcinomas revealed mutation of T286
to arginine and a deletion of carboxy-terminal residues 266-295, and screening of human
tumor-derived esophageal carcinoma cell lines also identified a P287 to alanine mutation
in three of these lines (Benzeno et al., 2006).
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Given the low frequency of cyclin D1 mutations that directly impact its turnover,
a natural prediction is the occurrence of inactivating mutations in its E3 ligase. The first
clue to cyclin D1 ligase involvement came from analysis of breast cancer cell lines
exhibiting increased cyclin D1 half-life without mutations disrupting phosphorylation.
These analyses revealed that MCF-7 and MDA-MB-231 cells lack B crystallin
expression as a consequence of chromosome 11 deletion, and tumor microarray analysis
of esophageal carcinomas revealed a reduction in both B crystallin and Fbx4 mRNA
levels in tumor tissues (Lin et al., 2006). Significantly, recent assessment of the FBX4
sequence in 116 esophageal carcinoma samples identified hemizygous missense
mutations in 14 percent of tumors. Many of these mutations reside within the FBX4
dimerization domain, while others target S12 in the N-terminus. Additionally, one
mutation was identified within the F box, which could result in production of a dominant
negative protein incapable of recruiting SKP1 and CUL1 (Barbash et al., 2008). Cyclin
D1 and Fbx4 alterations in human cancer are summarized in Figure 1.4 and Table 1.
The Fbx4 residues targeted in cancer are consistent with data revealing that Fbx4
dimerization following S12 phosphorylation and 14-3-3 binding is important for ligase
function, as described previously. Fbx4 phosphorylation correlates with low cyclin D1
expression during G2/M and early G1, with a marked decrease during cell cycle entry
due to growth factor-dependent GSK3 inhibition (Cross et al., 1995). Fbx4
phosphorylation increases again at the G1/S boundary as GSK3 becomes active and
temporally controls ligase activation and cyclin D1 phosphorylation. Consequently,
cyclin D1 phosphorylation is intimately tied to mitogen signaling and ligase activation,
with GSK3 at the apex of the regulatory pathway. Thus far, the tumorigenic potential of
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Fbx4 mutations has only been examined in vitro, revealing that such mutations are indeed
transforming (Barbash et al., 2008). However, the role of Fbx4 as a tumor suppressor has
not been elucidated in vivo. Work presented in chapter 3 of this thesis describes the first
genetic study to evaluate the relevance of Fbx4 function and provides substantial
evidence that Fbx4 is, in fact, a tumor suppressor in vivo.

Constitutively nuclear cyclin D1 drives genomic instability.
Nuclear accumulation of cyclin D1 resulting from impaired degradation drives
cellular transformation in vitro and B-cell lymphomagenesis in mice expressing cyclin
D1T286A driven by the E enhancer (Alt et al., 2000; Gladden et al., 2006).
Furthermore, recent evidence linked nuclear retention of active cyclin D1/CDK4
complexes with genomic instability. Nuclear cyclin D1/CDK4 activity in S-phase
promotes transcriptional repression of CUL4A and CUL4B, leading to stabilization of
CDT1, the pre-RC component that promotes loading of the replicative helicase during
G1, thereby facilitating maintenance of the MCM helicase on chromatin and subsequent
DNA re-replication. DNA re-replication, in turn, promotes accumulation of DNA damage
and activation of DNA damage checkpoint signaling. Checkpoint activation promotes
p53-dependent apoptosis initially, but provides a selective pressure for p53 functional
inactivation, resulting in genomic instability and neoplasia (Aggarwal et al., 2007).
Strikingly, impaired cyclin D1 ligase function results in nuclear accumulation of
active cyclin D1/CDK4 complexes, triggering cellular transformation analogous to cyclin
D1T286A (Barbash et al., 2008). Taken together, data elucidating the role of nuclear
cyclin D1 in neoplastic transformation support a model wherein disruption of cyclin D1
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phosphorylation or SCFFbx4 function generate genomic instability, ultimately driving
tumor formation (Figure 1.4). While it is clear that nuclear cyclin D1/CDK4 kinase
promotes CUL4 repression in S-phase, the precise mechanism underlying this event
remained elusive. Importantly, recent work identified a novel regulatory relationship
between
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methyltransferase
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protein
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(PRMT5/MEP50) methyltransferase complex and nuclear cyclin D1/CDK4. Briefly,
nuclear cyclin D1/CDK4 kinase phosphorylates MEP50, triggering increased intrinsic
methyltransferase activity of the PRMT5/MEP50 complex and subsequent histone
methylation at the CUL4 promoters, leading to transcriptional repression, CDT1
stabilization, and DNA re-replication (Aggarwal et al.). A mechanistic description and
biological implications of this process are presented in chapter 4 of this thesis.
Genomic instability is a hallmark of human cancer, implicated in initiation and
promotion of tumorigenesis, and chronic DNA damage checkpoint activation provides
selective pressure for deletion or mutation of tumor suppressors such as p53 (Bartkova J,
2005; Gorgoulis VG, 2005). DSB induction following genotoxic insults such as irradiation (IR) and stalled replication forks during normal replication activate the intraS and DNA replication checkpoints, respectively, thereby maintaining replication fidelity
(Figure 1.5A). PIKK kinases ATM (Ataxia Telangiectasia, Mutated) and ATR (ATM and
Rad3- Related) respond to DSBs and ssDNA, respectively, and signal directly and
through downstream effectors such as CHK1 and CHK2 to promote cell cycle arrest and
DNA repair (Kastan and Bartek, 2004).
Previous work implicated APC/C-mediated cyclin D1 destruction following DNA
damage in promoting p53-independent G1-phase cell cycle arrest (Agami and Bernards,
22

2000). Additionally, recent work suggested that ATM-dependent stabilization of the Fbox protein Fbxo31 promotes SCFFbxo31-mediated degradation of phosphorylated cyclin
D1 in G1-phase. Interestingly, this work suggested that ERK-dependent cyclin D1
phosphorylation promotes cyclin D1 recognition by Fbxo31 in melanoma cells (Santra et
al., 2009). Given the critical role for GSK3- and Fbx4-dependent cyclin D1 regulation
following the G1/S transition and ensuing DNA damage that occurs when cyclin D1 is
aberrantly maintained in the nucleus during S-phase, we proposed that cyclin D1 is
regulated by DNA damage following the G1/S transition, dependent upon Fbx4 (Figure
1.5B), (Pontano et al., 2008). The work presented in chapter 2 of this thesis supports this
model, demonstrating that rapid cyclin D1 destruction is essential to maintain genome
integrity following S-phase DNA damage.
Collectively, work over the past two decades established a model wherein
temporal CDK activity drives cell cycle progression, and tight control of CDK activators
and inhibitors by ubiquitin-mediated proteolysis keeps CDK activity in check. Critically,
disrupting this balance promotes aberrant CDK activation, an underlying event in
neoplastic transformation. This has been well demonstrated by cyclin D1/CDK4, as
impaired cyclin D1 degradation facilitates nuclear accumulation of active cyclin
D1/CDK4 kinase beyond the G1/S transition, thereby disrupting DNA replication fidelity
and promoting genomic instability. Although previous studies described this oncogenic
function of nuclear cyclin D1, the work presented in the next chapters further defines an
intricate relationship where aberrant nuclear cyclin D1/CDK4 activity modulates genetic
alterations necessary to promote genomic instability and neoplastic transformation.
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CHAPTER II:
GENOTOXIC STRESS-INDUCED CYCLIN D1 PHOSPHORYLATION AND
PROTEOLYSIS ARE REQUIRED FOR GENOMIC STABILITY

This chapter has been published in:
Molecular and Cellular Biology 28 (23): 7245-7258. December 2008.
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License Number: 2661040473670
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SUMMARY

While mitogenic induction of cyclin D1 contributes to cell cycle progression, ubiquitinmediated proteolysis buffers this accumulation and prevents aberrant proliferation.
Because failure to degrade cyclin D1 during S-phase triggers DNA re-replication, we
investigated regulation of cyclin D1 following genotoxic stress. These data reveal that
expression of cyclin D1 alleles refractory to phosphorylation- and ubiquitin mediated
degradation increase the frequency of chromatid breaks following DNA damage. Double
strand break-dependent cyclin D1 degradation requires ATM and GSK3, which in turn
mediate cyclin D1 phosphorylation. Phosphorylated cyclin D1 is targeted for proteasomal
degradation by SCFFbx4. Loss of Fbx4-dependent degradation triggers radio-resistant
DNA synthesis, thereby sensitizing cells to S-phase-specific chemotherapeutic
intervention. These data suggest that failure to degrade cyclin D1 compromises the intraS-phase checkpoint and suggest that cyclin D1 degradation is a vital cellular response
necessary to prevent genomic instability following genotoxic insult.
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INTRODUCTION

Mitogenic signals coordinated by the small GTP binding protein Ras induce Dtype cyclin expression during G1 phase of the cell cycle. Active cyclin D1/CDK4
complexes accumulate in the nucleus, triggering G1 progression via phosphorylationdependent inactivation of the retinoblastoma protein (Rb) and related pocket proteins
(Calbo et al., 2002; Harbour et al., 1999; Hatakeyama et al., 1994; Leng et al., 2002).
The cyclin D1/CDK4 kinase also facilitates activation of cyclin E/CDK2 through titration
of the CDK inhibitors p21CIP1 and p27KIP1, contributing to Rb phosphorylation by the
cyclin E/CDK2 kinase (Sherr, 1996).
After the G1/S transition, cyclin D1 activation is terminated by GSK3-dependent
threonine-286 (T286) phosphorylation, which triggers CRM1-dependent nuclear export
and ubiquitin-mediated proteolysis (Diehl et al., 1998). Proteolytic inactivation is
essential as cyclin D1 synthesis does not decrease in the presence of continuous growth
factor signaling (Matsushime et al., 1991). Cytoplasmic T286 phosphorylated cyclin D1
is targeted for degradation via the SCFFbx4-Bcrystallin E3 ubiquitin ligase, and recognition of
phosphorylated cyclin D1 is mediated by both Fbx4 and B crystallin (Lin et al., 2006).
Of the numerous cell cycle regulatory proteins, cyclin D1 is one of the most
frequently targeted in human cancer, with overexpression resulting from gene
amplification, chromosomal translocation, and protein stabilization (Sherr, 1996). Cyclin
D1 overexpression has been observed in various malignancies including carcinomas of
the breast, esophagus, colon, and lung (Barnes and Gillett, 1998; Bartkova et al., 1994a;
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Bartkova et al., 1995; Bartkova et al., 1994b; Ikeguchi et al., 2001; Jin et al., 2001).
While cyclin D1 overexpression occurs at a significant frequency, overexpression per se
is insufficient to drive neoplastic transformation. In contrast, cyclin D1 mutants that are
refractory to Fbx4-dependent proteolysis and accumulate in the nucleus are acutely
transforming (Alt et al., 2000; Gladden et al., 2006; Lin et al., 2007). Consistent with
disruption of cyclin D1 proteolysis functioning as an agonist of neoplastic growth,
mutations that disrupt cyclin D1 nuclear export and thus, ubiquitin-mediated proteolysis,
have been identified in human cancers (Benzeno and Diehl, 2004; Moreno-Bueno et al.,
2003).

In addition, recent screening of human esophageal tumor samples revealed

inactivating mutations in Fbx4, which will again drive nuclear cyclin D1 accumulation
(Barbash et al., 2008).
Genomic instability is a hallmark of human cancers implicated in initiation and
promotion of tumorigenesis. Double strand DNA breaks (DSBs) arise following irradiation (IR) or destabilization of stalled replication forks; checkpoint kinases
respond to such lesions, promoting cell cycle arrest and DNA repair (Kastan and Bartek,
2004). Impaired detection or repair of DSBs results in chromosomal translocations and
deletions, triggering genomic instability (Khanna and Jackson, 2001). The intra-S-phase
checkpoint responds to DSB induction occurring at loci outside actively replicating
DNA; failure to reduce the rate of DNA synthesis following such genotoxic insult results
in radio-resistant DNA synthesis (RDS), a phenotype associated with abrogated
checkpoint signaling through ATM (Ataxia Telangiectasia, mutated) and downstream
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effectors (Bartek et al., 2004). The primary mechanism of DSB-induced S-phase arrest
involves inhibition of unfired replication origins (Bartek et al., 2004; Costanzo et al.,
2000; Falck et al., 2002).
Recent evidence revealed that ubiquitylation refractory cyclin D1 accumulates as
an active D1/CDK4 kinase within the nucleus during S-phase, where it promotes DNA
re-replication, thereby linking cyclin D1 deregulation with S-phase perturbation
(Aggarwal et al., 2007). Previous work implicated cyclin D1 destruction following DNA
damage in promoting G1-phase cell cycle arrest (Agami and Bernards, 2000).
Consequently, we have investigated the role of cyclin D1 degradation for genomic
stability following genotoxic stress. The data provided reveal that cyclin D1 is rapidly
degraded in a phosphorylation-dependent manner following DSB induction, and failure
to degrade cyclin D1 compromises the intra-S-phase checkpoint response. Furthermore,
evidence is provided revealing that ATM signaling is critical for GSK3-dependent
cyclin D1 phosphorylation, highlighting the relevant signaling pathway that coordinates
DSB induction with cyclin D1 regulation.
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RESULTS

Expression of ubiquitylation-refractory cyclin D1T286A generates chromosomal
instability following DNA damage.
Transgenic mice expressing cyclin D1T286A driven by the E enhancer develop
B-cell lymphomas with significant aneuploidy and chromosomal translocations
(Aggarwal et al., 2007). Because cyclin D1T286A is refractory to ubiquitin-mediated
proteolysis (Diehl et al., 1997), we determined whether its expression also compromised
genomic integrity in response to transient exposure to DNA damaging agents. Nonmalignant splenocytes derived from E-D1T286A mice that were exposed to mitomycinC (MMC) exhibited a significant increase in chromatid breaks relative to non-transgenic
controls (Figure 2.1A). Similarly, exposure to hydroxyurea (HU) increased the incidence
of chromatid breaks in D1T286A-expressing cells compared to non-transgenic controls
(Figure 2.1B). Importantly, untreated non-transgenic and E-D1T286A splenocytes
exhibited infrequent chromatid breaks (Figure 2.1C), indicating synergy between cyclin
D1T286A and DNA damage in promoting genomic instability.

DSBs trigger phosphorylation-dependent cyclin D1 degradation.
The enhanced frequency of chromatid breaks in cells expressing cyclin D1T286A
might reflect the refractory nature of this allele to proteasome-dependent destruction
(Diehl et al., 1997). In fact, genotoxic stress normally triggers the rapid loss of cyclin D1,
which has been attributed to ubiquitin-mediated destruction during G1 phase (Agami and
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Bernards, 2000). Based on these findings, we investigated the mechanism governing
cyclin D1 loss following S-phase DNA damage. NIH3T3 cells were treated with HU, a
compound that stalls DNA replication by depleting nucleotide pools and generates double
breaks as a consequence of replication fork collapse (Bianchi et al., 1986; Lundin et al.,
2002). HU treatment promoted a rapid decline in both endogenous cyclin D1 protein and
exogenously expressed, Flag-tagged cyclin D1 (Figure 2.2A; data not shown). Cyclin D1
mRNA levels remained constant, consistent with post-translational regulation (data not
shown). We subsequently assessed cyclin D1 loss at varied HU concentrations. Cyclin
D1 loss was readily apparent by 0.5mM HU and was maximal at 1-2mM HU (Figure
2.2A); an intermediate dose of 2mM was selected for further analyses.
We next determined whether proteasome-resistant, non-phosphorylatable
D1T286A was refractory to DNA damage-dependent downregulation. NIH3T3 cells
stably expressing equivalent levels of either wild type Flag-D1 (3T3-D1) or FlagD1T286A (3T3-D1T286A) were utilized (Diehl et al., 1997). Treatment of cells
synchronously proliferating through S-phase with 2mM HU triggered loss of wild type
cyclin D1 protein; loss was inhibited by concurrent application of MG132, revealing
proteasome-dependence (Figure 2.2B). In contrast, D1T286A levels were constant
following HU treatment (Figure 2.2 B, C). If accelerated loss of cyclin D1 is determined
by increased proteolysis, the cyclin D1 half-life should decrease following DNA damage.
S-phase NIH3T3 cells were left untreated or treated with 2mM HU for 30 minutes,
followed by addition of cycloheximide (CHX). Western analysis revealed that the cyclin
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D1 half-life was reduced following HU compared to untreated cells (Figure 2.2D). These
results support a model wherein DNA damage induced by HU triggers phosphorylationand proteasome-dependent degradation of cyclin D1.
We then ascertained whether cyclin D1 proteolysis required the generation of
DSBs. Asynchronously proliferating 3T3-D1 or 3T3-D1T286A cells were subjected to
10Gy gIR and cyclin D1 levels were assessed by immunoblot. IR, like HU, triggered the
rapid loss of wild type cyclin D1 but not D1T286A (Figure 2.2E). Similar to IR,
bleomycin treatment also induced rapid, phosphorylation-dependent destruction of cyclin
D1 (Figure 2.2F), implying that DSBs promote cyclin D1 degradation.
To directly address whether stalled DNA replication without DSB induction can
trigger cyclin D1 destruction, cyclin D1 stability was compared for aphidicolin and HU
treatment. NIH3T3 or 3T3-D1 cells were synchronized by serum starvation for 24 hours
and serum stimulated for 15 hours to enter S-phase; cells were then subjected to shortterm, low dose aphidicolin treatment to promote the accumulation of single strand DNA
without collapsing replication forks (Liu et al., 2003) or 2mM HU, previously shown to
induce cyclin D1 degradation (Figure 2.2A-D). A significant percentage (>80%) of cells
were in S-phase throughout the duration of treatment with DNA damaging agents as
determined by flow cytometry (data not shown). In contrast to HU or IR, cyclin D1
levels remained stable following aphidicolin treatment (Figure 2.2G, H). Significantly,
cyclin D1 is only phosphorylated in a damage-dependent manner following HU treatment
(Figure 2.2G), consistent with activation of Chk2 signaling as an indicator of DSB
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induction. Chk1 is activated following both aphidicolin and HU treatment, consistent
with stalled replication; however, a mobility shift in Chk2 due to ATM-dependent
phosphorylation was not observed in aphidicolin-treated cells, indicating that this shortterm treatment fails to activate the ATM pathway (Figure 2.2G). Collectively, these data
demonstrate that stalled replication is not sufficient to induce cyclin D1 loss despite
activation of the ATR (ATM and Rad3-related)-Chk1 DNA damage response pathway.
To ensure that the stability of D1T286A was not a reflection of ectopic
expression, we also examined cyclin D1 response to DSBs in human tumor-derived cells
harboring either wild type D1 (KYSE520) or an endogenous cyclin D1P287A allele
(TE3/TE7) (Benzeno et al., 2006). KYSE520 cells exhibited rapid cyclin D1 degradation
following IR, while cyclin D1P287A, expressed in TE3 and TE7 cells, was refractory to
degradation following moderate or high IR dose (Figure 2.3A-B). Cyclin D2 and cyclin
E degradation was not triggered by irradiation, consistent with previous work indicating
that DNA damage-induced regulation is restricted to cyclin D1 (Agami and Bernards,
2000); Figure 2.3C). Collectively, our data suggest that bona fide DNA breaks are a
prerequisite for cyclin D1-specific proteolysis in response to DNA damage.

GSK3 catalyzes cyclin D1 T286 phosphorylation following genotoxic stress.
The stability of D1T286A to DSB-mediated destruction suggests that
phosphorylation of this residue is essential for genotoxic stress-induced cyclin D1 loss. If
so, genotoxic stress should trigger increased T286 phosphorylation (p-T286). Indeed,
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both irradiation (Figure 2.4A) and bleomycin (Figure 2.2F) triggered an increase in pT286 prior to cyclin D1 proteolysis. Because the cyclin D1 E3 ligase is cytoplasmic,
ubiquitin-mediated proteolysis requires both p-T286 and cytoplasmic redistribution (Alt
et al., 2000; Diehl et al., 1997; Lin et al., 2006). If genotoxic stress utilizes the same
machinery to eliminate cyclin D1, then nuclear export-deficient cyclin D1 mutants should
accumulate as p-T286 proteins in the nucleus. To test this notion, we examined the
regulation of cyclin D1-290/95A, a cyclin D1 mutant harboring an inactive nuclear
export sequence, but retaining the GSK3 phosphorylation site (Benzeno and Diehl,
2004). Consistent with our hypothesis, D1-290/95A was resistant to DSB-dependent
proteolysis and accumulated as a phosphorylated protein (Figure 2.4A, right panel).
GSK3 catalyzes phosphorylation of T286 at the G1/S boundary to promote
cyclin D1 loss (Diehl et al., 1998). To determine whether GSK3 mediates DSBdependent T286 phosphorylation, we initially utilized a kinase-dead GSK3 (kdGSK3)
allele. Cyclin D1 phosphorylation was assessed 20 minutes after IR in order to visualize
this highly labile protein in the absence of proteasome inhibition; importantly, significant
cyclin D1 degradation is not evident at this early time following DNA damage in
NIH3T3 cells (Figure 2.2G, H). Expression of kdGSK3 attenuated T286
phosphorylation following IR (Figure 2.4B). As independent assessment of GSK3
dependence, NIH3T3 cells were treated with LiCl (Stambolic et al., 1996) or a small
molecule inhibitor of GSK3, SB216763. Both inhibitors attenuated cyclin D1
phosphorylation following IR (Figure 2.4C). As a third method for assessing GSK339

dependent T286 phosphorylation, shRNA technology was utilized to attenuate GSK3
expression. 293T cells were transfected with vectors encoding cyclin D1 and CDK4
along with control or GSK3-specific shRNA. Immunoblotting confirmed a reduction in
GSK3 protein levels (Figure 2.4D). Attenuation of GSK3 expression significantly
reduced cyclin D1 phosphorylation compared to control shRNA-transfected cells (Figure
2.4D). Collectively, three independent methods of GSK3 inhibition reveal that this
kinase regulates T286 phosphorylation following DNA damage.
Since cyclin D1 is rapidly phosphorylated following DNA damage, we
determined whether GSK3 kinase activity was increased following IR. Previously
published work revealed an increase in GSK3 kinase activity following UV irradiation
(Lee et al., 2007). IP-kinase reactions from irradiated NIH 3T3 cells revealed increased
GSK3 kinase activity following IR (Figure 2.4E). GSK3 can also phosphorylate
cyclin D2 on threonine 280 (T280) and thereby trigger its proteasome-dependent loss
(Kida et al., 2007). Consequently, we determined whether cyclin D2 phosphorylation was
regulated by IR. Cyclin D2 T280 phosphorylation was not induced above basal levels
following IR (data not shown). This finding suggests that while GSK3 kinase activity
is increased following DNA damage, additional regulatory mechanisms exist to allow
GSK3-dependent cyclin D1 phosphorylation specifically. A second kinase, p38SAPK, has
been implicated in stress-induced cyclin D1 phosphorylation (Casanovas et al., 2000),
and DNA damage increases p38SAPK activity (Raman et al., 2007). We therefore
determined whether p38SAPK contributes to DNA damage-dependent cyclin D1
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destruction. Significantly, p38 inhibition did not stabilize cyclin D1 protein, suggesting
that p38 is not a key regulator of DSB-induced cyclin D1 loss (Figure 2.4F).
Collectively, these results indicate that GSK3 is the primary kinase responsible for
DSB-dependent cyclin D1 phosphorylation.

ATM signaling coordinates DSB induction with cyclin D1 phosphorylation.
Because the ATM kinase is the primary signal transducer following DSB
induction, we determined whether either ATM or the related kinase ATR (which
responds to stalled replication) is necessary for cyclin D1 loss following genotoxic stress.
We utilized ATM+/+ or ATM-/- murine fibroblasts for this analysis. To facilitate detection,
we expressed Flag-tagged cyclin D1 in these cells as our analysis has revealed that
ectopic protein is regulated as effectively as endogenous (see Figure 2.2). In ATM-/cells, cyclin D1 levels remained elevated, while cyclin D1 was degraded in matched
passage ATM+/+ cells following stress (Figure 2.5A). Consistent with ATM coordinating
cyclin D1 loss, cyclin D1 phosphorylation was only induced in ATM+/+ cells following
IR (Figure 2.5B). Furthermore, pharmacological inhibition of ATM with KU55933 also
inhibited cyclin D1 phosphorylation (Figure 2.5C).
Since ATM and Mre11-dependent DNA resection following DSBs will also
trigger activation of ATR (Jazayeri et al., 2006), we determined whether ATR signaling
contributed to DSB-induced cyclin D1 loss. Stalled DNA replication induced by
aphidicolin treatment was insufficient to induce cyclin D1 phosphorylation or
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degradation despite activation of Chk1, a checkpoint kinase downstream of ATR (Figure
2.2G, H) suggesting that the ATR pathway does not regulate cyclin D1. The role of ATR
was directly assessed using fibroblasts harboring a tamoxifen inducible ATR allele,
ATRflox/- (Brown and Baltimore, 2003). Cells were treated with DMSO or 200nM 4-OH
tamoxifen (TAM) for 24 hours to induce ATR deletion, followed by 12-hour incubation
to allow for ATR depletion. Cyclin D1 levels were equivalent in the presence or absence
of ATR following IR (Figure 2.6A) or HU treatment (Figure 2.6B). Additionally,
attenuation of endogenous ATR expression via ATR-specific siRNA did not alter cyclin
D1 phosphorylation or degradation following IR, despite efficient knockdown (Figure
2.6C). Taken together, these data reveal that cyclin D1 regulation following DNA
damage occurs downstream of ATM activation.
Because Chk2 is a primary effector of ATM (Kastan and Bartek, 2004), we
assessed whether activation of Chk2 is required for cyclin D1 loss. Knockdown of Chk2
via siRNA modestly attenuated, but did not abrogate DSB-dependent cyclin D1
destruction (Figure 2.7A). We also assessed whether inhibition of Chk1, the downstream
ATR effector, affects cyclin D1 phosphorylation and loss following DSB induction
(Figure 2.7B, C).

Significantly, use of the Chk1-specific inhibitor SB218078 or

attenuation of Chk1 expression via shRNA did not alter cyclin D1 phosphorylation or
degradation in S-phase cells treated with HU (Figure 2.7B and C, respectively). Finally,
we determined whether there is synergy between Chk1 and Chk2 in regulating cyclin D1
following DSB induction. siRNA-mediated knockdown of Chk2 modestly attenuates
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cyclin D1 degradation at early time points in U20S cells; in contrast, cyclin D1 levels are
equivalent in control and Chk2 siRNA conditions at later time points (Figure 2.7D).
Significantly, addition of a Chk1 inhibitor, SB218078, did not further stabilize cyclin D1
levels, suggesting that Chk1 and Chk2 activity is not synergistic in regulating cyclin D1
(Figure 2.7D). These results suggest that Chk2 may play a minor or indirect role in cyclin
D1 regulation; however, additional ATM-dependent effectors also function in DNA
damage-induced cyclin D1 degradation. Collectively, our data support a model wherein
ATM activation following DSB induction is necessary for cyclin D1 phosphorylation and
subsequent degradation. However, future investigation of regulators downstream of
ATM, including Chk2, is important to completely delineate the DNA damage-specific
signaling network that coordinates cyclin D1 destruction.

SCFFbx4-B

crystallin

is required for cyclin D1 degradation following DNA damage.

SCFFbx4-Bcrystallin was recently shown to direct p-T286-dependent ubiquitylation of
cyclin D1 in both fibroblasts and epithelial cells (Lin et al., 2006). Fbx4 and B crystallin
serve as substrate-specific adaptors that recognize phosphorylated cyclin D1. To directly
assess the role of Fbx4 and B crystallin in DNA damage-induced cyclin D1 proteolysis,
we utilized NIH3T3 cells wherein either Fbx4 or B crystallin have been stably knocked
down by shRNA (Lin et al., 2006).

Knockdown of either Fbx4 or B crystallin

significantly attenuated cyclin D1 proteolysis following DNA damage (Figure 2.8A, B).
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Previous work revealed disruption of the B crystallin locus in several breast
cancer-derived cell lines (Lin et al., 2006). We utilized one such cell line, MDA-MB 231
cells, to independently determine whether B crystallin is required for cyclin D1
degradation following DSB induction. Consistent with the results obtained utilizing
NIH3T3 cells expressing B crystallin shRNA, irradiation of MDA-MB 231 cells did not
trigger cyclin D1 loss, while re-introduction of exogenous B crystallin restored DNA
damage-induced cyclin D1 degradation (Figure 2.8C, compare 1h and 3h treatment in left
panel to corresponding treatments in right panel).
While our data reveal cyclin D1 destruction following DSB initiation to be
dependent upon p-T286 and the SCFFbx4-Bcrystallin ligase, the anaphase promoting
complex/cyclosome (APC/C) has also been implicated in the regulation of cyclin D1
degradation during G1 phase following IR (Agami and Bernards, 2000). Importantly,
the cell line utilized for these studies, MCF7, lacks endogenous B crystallin expression,
thereby rendering the Fbx4 ligase inactive toward cyclin D1 in these cells (Lin et al.,
2006). Since cyclin D1 turns over, albeit with slower kinetics in this cell line, an
alternative degradation pathway is likely. To determine if APC/C contributes to cyclin
D1 degradation in cells expressing a functional Fbx4-dependent ligase, we mutated L32
of cyclin D1 within the putative destruction box (Agami and Bernards, 2000) to alanine
and examined cyclin D1 stability following DNA damage. The D1-L32A mutant is
degraded similarly to wild type protein (Figure 2.8D); we also demonstrate that this
mutant has impaired CDK4 binding potential, consistent with disruption of residues
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proximal to the cyclin box (Figure 2.8D). Additionally, D1-L32A is degraded in MCF7
cells reconstituted with exogenous B crystallin (data not shown), suggesting that
restored SCFFbx4-Bcrystallin ligase activity shifts cyclin D1 destruction from alternative
mechanisms to the phosphorylation-dependent destruction pathway.
Recent work revealed that disruption of SCFFbx4-B crystallin allows accumulation of
cyclin D1 in the nucleus, and impaired ligase function results in neoplastic transformation
(Barbash et al., 2008). We therefore determined whether knockdown of Fbx4 sensitizes
cells to chromatid breaks following DNA damage, analogous to cyclin D1T286A (Figure
2.1B). NIH3T3 cells stably expressing vector control, Fbx4 shRNA, or cyclin D1T286A
were synchronized and treated with HU during S-phase. Metaphase spreads were then
prepared and analyzed for chromatid breaks. In agreement with splenocytes derived from
E-D1T286A transgenic mice, NIH3T3 cells expressing cyclin D1T286A exhibited a
significant increase in chromatid breaks following HU treatment. Analogous with cyclin
D1T286A expression, knockdown of Fbx4 also results in increased chromatid breaks
following HU compared to the vector control (Figure 2.8E, F).

Cyclin D1 stabilization compromises the intra-S-phase checkpoint.
Cyclin D1 mutants refractory to ubiquitin-mediated proteolysis accumulate in the
nucleus as active cyclin D1/CDK4 complexes and drive DNA re-replication. This
deregulated replication results from stabilization of the pre-RC licensing factor CDT1,
which promotes loading of the MCM helicase (Aggarwal et al., 2007). Cdt1 degradation
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in response to DNA damage is necessary to inhibit replication of damaged DNA (Higa et
al., 2003; Hu et al., 2004; Nishitani et al., 2006). Since cyclin D1 is rapidly degraded
following DSB induction, we considered whether failure to degrade cyclin D1 would
impede CDT1 destruction. To test this notion, we assessed CDT1 stability following
DNA damage; HeLa cells were transiently transfected with wild type or cyclin D1T286A
constructs along with CDK4 and treated with bleomycin. Cdt1 levels were attenuated in
the presence of wild type cyclin D1, while D1T286A expressing cells exhibited CDT1
stabilization up to 2 hours of bleomycin treatment (Figure 2.9A), consistent with
published results (Aggarwal et al., 2007).
Maintenance of CDT1 should have a direct impact on MCM chromatin loading
following DNA damage. We assessed chromatin retention of MCM complexes in human
cancer-derived cells that express endogenous wild type cyclin D1 or P287A. MCM3 (a
surrogate marker of MCM loading) dissociates from chromatin with a concomitant
increase in soluble MCM3 protein following DNA damage in the presence of wild type
cyclin D1; however, MCM3 was stabilized on chromatin in P287A-expressing cells
(Figure 2.9B). PCNA serves as a representative chromatin bound protein, and loading of
the chromatin fraction was also examined by Ponceau S stain. These data suggest that
improper maintenance of pre-RC components on chromatin contributes to cyclin
D1T286A-driven perturbations in DNA replication, a finding consistent with previously
published reports (Aggarwal et al., 2007).
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To directly determine whether cyclin D1 stabilization overrides the intra-S-phase
checkpoint, we assessed RDS in cells expressing equivalent steady-state levels (prior to
DNA damage) of either wild type cyclin D1 or D1T286A (Figure 2.2E). DNA synthesis
decreases significantly following IR in naïve 3T3 and 3T3-D1 cells (p<0.05); however,
DNA synthesis was not significantly decreased in D1T286A expressing cells (Figure
2.9C). We also measured RDS in NIH3T3 cells where Fbx4 levels are reduced through
shRNA technology. Analogous with degradation-refractory D1T286A, knockdown of
Fbx4 or B crystallin promoted RDS (Figure 2.9D). In contrast, knockdown of Fbx4 in
cyclin D1-/- fibroblasts failed to trigger RDS (Figure 2.9E, F), which is consistent with
cyclin D1 as the primary regulatory target of Fbx4 pertaining to cell cycle progression.
Although RDS is often associated with a failure of cells to inhibit CDK2, our analysis
revealed effective inhibition of CDK2 kinase in D1T286A expressing cells (data not
shown) suggesting that maintenance of cyclin D1/CDK4 activity directly contributes to
the RDS phenotype.
Since cyclin D1T286A expression promotes RDS, we hypothesized that cells
expressing stabilized cyclin D1 would be sensitized to the S-phase-specific
chemotherapeutic agent camptothecin (CPT). To address this hypothesis, 3T3-D1 or
D1T286A cells were treated with 25 or 50μM CPT for 24 or 48 hours; cells were
harvested, stained with propidium iodide, and subjected to FACS analysis to determine
cell cycle distribution. A significant increase in sub-G1 cells was observed following
CPT treatment for 48h (p<0.05), providing evidence that cyclin D1T286A-expressing
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cells are sensitized to CPT (Figure 2.9G). Taken together, the RDS phenotype and Sphase chemotherapy-sensitivity observed in D1T286A-expressing cells highlights a
potential therapeutic strategy for tumors exhibiting stabilized cyclin D1.

48

DISCUSSION
Recent work revealed that alterations in post-translational control of cyclin D1
contribute to neoplastic growth in model systems and in human cancers (Barbash et al.,
2008; Benzeno et al., 2006; Gladden et al., 2006; Lin et al., 2006).

Cyclin D1

accumulation in the nuclear compartment, where it functions as an allosteric activator of
CDK4, contributes directly to G1 progression and cell proliferation. Importantly,
accumulation is limited by ubiquitin-mediated proteolysis catalyzed by SCFFbx4-Bcrystallin,
and loss of proteolytic control contributes to neoplastic growth (Diehl et al., 1997; Lin et
al., 2006). The findings presented here reveal that nuclear stabilization of cyclin D1
compromises the intra-S-phase checkpoint following DNA damage. While cyclin D1 is
an inherently unstable protein, genotoxic stress further accelerates its proteolysis in a
manner that depends upon GSK3-mediated p-T286 and ubiquitylation by the SCFFbx4Bcrystallin

E3 ligase. Mutations that impair cyclin D1 phosphorylation or inactivate SCFFbx4-

Bcrystallin

result in the accumulation of active cyclin D1/CDK4 in the nucleus, which in

turn, impairs checkpoint-dependent inhibition of DNA replication.

Ultimately, the

ensuing RDS results in the accumulation of chromatid breaks.
T286 phosphorylation is required for both cell cycle- and DNA damage-mediated
destruction of cyclin D1. While additional kinases have been implicated as regulators of
p-T286 (Casanovas et al., 2000; Kwak et al., 2005; Okabe et al., 2006), our data provide
strong evidence for GSK3 as the T286 kinase. GSK3 inhibition via LiCl treatment
enriches nuclear cyclin D1 (Alt et al., 2000); LiCl, a small molecule GSK3 inhibitor
(SB216763), kdGSK3, and shRNA all significantly attenuate DNA damage-induced
T286 phosphorylation. Importantly, inhibition of the two additional kinases implicated
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as regulators of cyclin D1, IKK (data not shown) and p38 (Figure 2.4F), had no effect
on cyclin D1 phosphorylation or degradation in response to DSB induction.
GSK3 contributes directly to cyclin D1 regulation in multiple ways. First,
phosphorylation of T286 is required for CRM1-mediated nuclear export (Alt et al., 2000).
Second, phosphorylated cyclin D1 is recognized by Fbx4, the specificity factor for the
SCF E3 ligase, once re-localized to the cytoplasm (Lin et al., 2006). Our data reveal that
shRNA-mediated reduction of either Fbx4 or B crystallin stabilizes cyclin D1 in the
presence of DSBs. Consistently, cyclin D1 is also refractory to degradation in breast
cancer cells lacking endogenous B crystallin expression, while reintroduction of
exogenous B crystallin restores cyclin D1 turnover. Collectively, these data support a
model wherein upregulation of GSK3-dependent cyclin D1 phosphorylation following
genotoxic stress targets the protein for SCFFbx4-mediated destruction.
Previous work implicated the anaphase promoting complex/cyclosome (APC/C)
in DNA damage-induced cyclin D1 degradation (Agami and Bernards, 2000). A putative
RxxL destruction box in the N-terminus of cyclin D1 was identified as being responsible
for directing APC/C-dependent degradation. Our work reveals that mutation of T286,
loss of Fbx4, or inhibition of GSK3 impairs DSB-mediated cyclin D1 loss; we also
assessed the potential contribution of the RxxL motif. Leucine 32 to alanine (L32A)
mutation did not attenuate DSB-induced loss. Importantly, this mutation profoundly
impairs CDK4 binding, most likely resulting from disruption of protein structure just
proximal to the cyclin box. Thus, alterations in folding of this mutant could contribute to
its stabilization under some conditions.

50

While mutations near the cyclin box clearly alter structural interactions with
CDK4, this may not be the only reason accounting for discrepancies regarding the role of
different E3 ligases in cyclin destruction. An additional possibility is that this previous
work utilized MCF7 cells, a cell line lacking B crystallin (Lin et al., 2006), thereby
inactivating the SCFFbx4-B

crystallin

ubiquitin ligase.

While cyclin D1 proteolysis is

significantly attenuated in these cells, restoration of B crystallin rescues both mitogen
and DSB-dependent cyclin D1 proteolysis (data not shown). A third E3 ligase utilizing
Fbw8 as a specificity co-factor has been implicated in regulating cyclin D1 (Okabe et al.,
2006). We have not assessed Fbw8 directly due to a lack of suitable antibodies and
cannot rule out its potential role in regulating D1. However, Cul7, a core component of
the Fbw8 ligase, is undetectable in NIH3T3 cells (Kasper et al., 2005), and our data
revealing that knockdown of either Fbx4 or B crystallin is sufficient to inhibit cyclin D1
proteolysis emphasizes their requisite role in this regulatory process.
During S-phase, DNA must be replicated with high fidelity to ensure error-free
propagation of genetic material. DSBs resulting from various stresses invoke a
checkpoint that attenuates cell cycle progression until DNA is repaired (Bartek et al.,
2004). The intra-S-phase checkpoint is characterized by replication fork stalling,
inhibition of origin firing, and accumulation of single strand DNA, promoting ATR
activation; in contrast, the accumulation of DSBs, regardless of replication status, triggers
ATM activation (Bartek et al., 2004; Kastan and Bartek, 2004). Strikingly, inhibition of
cyclin D1 degradation impairs checkpoint response and cells exhibit an RDS phenotype,
implying checkpoint failure. The RDS phenotype observed in cyclin D1T286Aexpressing cells is accompanied by CDT1 stabilization, which is dependent upon CDK4
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activation by cyclin D1. Ultimately, the continued presence of CDT1 contributes to
retention of MCM helicase on chromatin, suggesting that the presence of this mutant
within the nucleus perturbs pre-RC disassembly following DNA damage. The
significance of the cyclin D1T286A RDS phenotype is highlighted by increased presence
of chromatid breaks in primary splenocytes treated with DNA damaging agents.
While the ability of constitutively nuclear D1T286A to promote CDT1
stabilization is clear, how does inactivation of Fbx4 ligase in cells harboring wild type
cyclin D1 equate with the same biochemical function? Importantly, published work
reveals that inactivation of SCFFbx4-B

crystallin

results in the nuclear accumulation of

endogenous cyclin D1/CDK4 kinase leading to CDT1 stabilization and function in both
cycling cells and following DSB generation (Aggarwal et al., 2007; Barbash et al., 2008).
Accordingly, our data are consistent with these findings and further reveal the retention
of MCM on chromatin following DSBs. Additionally, shRNA-mediated attenuation of
Fbx4 expression promotes an RDS phenotype that correlates with increased genomic
instability following treatment with DNA damaging agents.
Previous work suggested that inhibition of cyclin D1/CDK4 activity is critical for
genotoxic stress induced cell cycle arrest (Agami and Bernards, 2000). Significantly,
cyclin D1-driven DNA re-replication requires CDK4 kinase activity (Aggarwal et al.,
2007). Our findings here not only reveal the molecular nature of the ligase that regulates
cyclin D1 but also importantly provide mechanistic insight with regard to the
consequences of the accumulation of stabilized cyclin D1 and thus, cyclin D1/CDK4
kinase. In the absence of CDK4 kinase, pre-malignant cells could successfully halt DNA
replication, thereby reducing genomic instability that may promote transformation.
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Given the RDS phenotype associated with maintenance of cyclin D1 protein
following genotoxic stress, it is not surprising that ATM signaling is required to
coordinate cyclin D1 destruction. Consistent with our model of DSB induction as a
prerequisite for cyclin D1 phosphorylation and destruction, accumulation of single strand
DNA and subsequent ATR activation is insufficient to direct cyclin D1 loss.
Significantly, damage-induced cyclin D1 phosphorylation and destruction are abrogated
in ATM null cells and use of an ATM-specific inhibitor dramatically attenuates cyclin D1
phosphorylation. However, it is possible that ATR could contribute to ATM activation
following fork stalling (Stiff et al., 2006). The fact that ATR depletion did not attenuate
cyclin D1 phosphorylation/degradation and that cyclin D1 is not phosphorylated
following stress that does not trigger DSB implies that cyclin D1 loss is ATM-dependent
and ATR-independent.
While ATM is required for DNA damage-induced cyclin D1 phosphorylation, the
precise effector-signaling network remains unclear. Chk2 appears to function in the
regulation of cyclin D1 degradation at early time points following IR; however, Chk2
knockdown/inhibition fails to rescue cyclin D1 degradation at later time points after
damage. As loss of ATM and GSK3 function to stabilize cyclin D1 at all time points,
this result suggests an alternative ATM effector in the mediation of GSK3-dependent
cyclin D1 degradation. Delineating the molecular signaling network connecting ATM
with cyclin D1 T286 phosphorylation is an exciting area for future study.
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CHAPTER III:
THE FBX4 TUMOR SUPPRESSOR REGULATES CYCLIN D1
ACCUMULATION AND PREVENTS NEOPLASTIC TRANSFORMATION
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SUMMARY
SCF E3 ubiquitin ligase complexes modulate the accumulation of key cell cycle
regulatory proteins. Following the G1/S transition, SCFFbx4 targets cyclin D1 for
proteasomal degradation, a critical event necessary for DNA replication fidelity.
Deregulated cyclin D1 drives tumorigenesis, and inactivating mutations in Fbx4 have
been identified in human cancer, suggesting that Fbx4 may function as a tumor
suppressor. Fbx4+/- and Fbx4-/- mice succumb to multiple tumor phenotypes including
lymphomas, histiocytic sarcomas, and less frequently, mammary tumors and
hepatocellular carcinomas. Tumors and pre-malignant tissue from Fbx4+/- and Fbx4-/mice exhibit elevated cyclin D1, consistent with cyclin D1 as a target of Fbx4. Molecular
dissection of the Fbx4 regulatory network in murine embryonic fibroblasts (MEFs)
revealed that loss of Fbx4 results in cyclin D1 stabilization and nuclear accumulation
throughout cell division. Increased proliferation in early passage primary MEFs is
antagonized by DNA damage checkpoint activation, consistent with nuclear cyclin D1driven genomic instability. Furthermore, Fbx4-/- MEFs exhibited increased susceptibility
to Ras-dependent transformation in vitro, analogous to tumorigenesis observed in mice.
Collectively, these data reveal a requisite role for the SCFFbx4 E3 ubiquitin ligase in
regulating cyclin D1 accumulation, consistent with tumor suppressive function in vivo.
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INTRODUCTION
Cell cycle progression is intricately controlled by coordinated expression and
ubiquitin (Ub)-dependent degradation of key regulatory proteins. Ubiquitylation of target
substrates requires the concerted activity of an Ub-activating enzyme (E1), recruitment of
an Ub-conjugating enzyme (E2), and an E3 ubiquitin ligase. Although some E3 ubiquitin
ligases directly mediate transfer of ubiquitin, for example the HECT-domain family,
many E3 ligases function as multi-subunit complexes that bridge the charged E2 enzyme
with a given substrate (Hershko and Ciechanover, 1998). The SKP1-CUL1-F-box (SCF)
family of E3 ubiquitin ligases promotes polyubiquitylation of mainly phosphorylated
substrates, including mediators of the G1/S phase transition (Deshaies, 1999; Skowyra et
al., 1997). Substrate specificity of SCF E3 ligases is conferred by the F-box protein,
which serves as a molecular adapter bridging substrate molecules with the core ligase
machinery and E2 enzyme. F-box proteins contain a conserved F-box domain within the
N-terminal region, required for specific SKP1 binding and recruitment of core ligase
components CUL1, RBX1, and E2, as well as a substrate-recognition domain within the
C-terminus (Nakayama and Nakayama, 2005; Winston et al., 1999a).
The F-box protein Fbx4 facilitates ubiquitylation of cyclin D1 following the G1/S
transition (Lin et al., 2006). Similar to Fbw7, an ubiquitin ligase for substrates including
cyclin E, c-Myc, and Notch (Tang et al., 2007; Zhang and Koepp, 2006), and -TrCP, an
IB E3 ligase (Suzuki et al., 2000), Fbx4 undergoes dimerization; however, in contrast to
Fbw7,

Fbx4

dimerization

occurs

in

a

cell

cycle-dependent

manner.

Fbx4

homodimerization occurs following GSK3-dependent phosphorylation on serine 12,
resulting in ligase activation at the G1/S transition and subsequent ubiquitylation of
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phosphorylated cyclin D1 (Barbash et al., 2008; Lin et al., 2006). Critically, failure to
degrade cyclin D1 following the G1/S transition permits active cyclin D1/CDK4 nuclear
accumulation and drives cell transformation (Aggarwal et al., 2007; Aggarwal et al.; Alt
et al., 2000). While cyclin D1 overexpression occurs in multiple human malignancies
(Bani-Hani et al., 2000; Bartkova et al., 1994a; Bartkova et al., 1995; Bartkova et al.,
1994b; Gillett et al., 1994; Herman et al., 1995; Hibberts et al., 1999; Hosokawa and
Arnold, 1998; Hosokawa et al., 1999; Jin et al., 2001), overexpression of wild type cyclin
D1 in an Fbx4-proficient system is insufficient to drive spontaneous transformation (Alt
et al., 2000; Barbash et al., 2008), supporting a model wherein cytoplasmic recognition of
phosphorylated cyclin D1 by Fbx4 is sufficient to maintain cellular integrity.
Cyclin D1 mutations that impede its timely degradation and trigger constitutively
nuclear accumulation promote neoplastic growth (Aggarwal et al., 2007; Alt et al., 2000;
Barbash et al., 2008; Benzeno et al., 2006; Lu et al., 2003); however such mutations are
rare in human cancer. Recent work identified inactivating Fbx4 mutations in human
cancers that impair ligase phosphorylation and dimerization; such tumors exhibit marked
cyclin D1 nuclear accumulation, highlighting a novel mechanism for cyclin D1
deregulation in cancer (Barbash et al., 2008). Consistent with these findings, in vitro
studies revealed that shRNA-mediated knockdown of Fbx4 promotes anchorageindependent growth, a phenotype that is rescued by loss of cyclin D1 (Barbash et al.,
2008). Taken together, these findings suggest that the Fbx4 protein functions as a tumor
suppressor, preventing aberrant cyclin D1 accumulation during S-phase.
To investigate the role of Fbx4 as a putative tumor suppressor in vivo, we ablated
the murine Fbx4 gene. Fbx4-/- mice are viable and lack major developmental defects;
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however, both Fbx4+/- and Fbx4-/- mice succumb to multiple tumor phenotypes, with a
marked increase in cyclin D1 levels in pre-malignant and tumor tissue. Likewise, Fbx4-/MEFs exhibit cyclin D1 stabilization and subsequent nuclear localization, with
concomitant induction of DNA damage-associated nuclear foci, consistent with a model
wherein nuclear cyclin D1/CDK4 kinase drives genomic instability. Finally, Fbx4
deficiency facilitates cellular transformation in vitro, supporting the notion that Fbx4 is a
bona fide tumor suppressor.

67

RESULTS
Generation of Fbx4-/- mice.
To directly assess the tumor suppressor function of Fbx4 we generated a targeting
vector to facilitate deletion of murine Fbx4 by homologous recombination in embryonic
stem (ES) cells. LoxP sites were inserted flanking exon 2, with a downstream neomycin
(Lan et al.) cassette flanked by a third LoxP site. Cre-mediated recombination and
deletion of exon 2 removes sequences critical for assembly of a functional ligase F-box
and results in a frameshift and premature termination (Figure 3.1A). The targeting
construct was electroporated into ES cells, and correctly targeted clones were identified
by Southern hybridization (Figure 3.1B). Four ES clones out of 132 exhibited a correctly
targeted allele, with complete excision of the Neo cassette and exon 2. ES cell clones
harboring a correctly targeted allele with a normal karyotype were injected in C57BL/6
blastocysts, and two clones resulted in germline transmission. Chimeric mice were then
intercrossed with EIIa-Cre transgenic mice to generate Fbx4 heterozygous progeny
(genotype confirmation, Figure 3.1C). Both Fbx4+/- and Fbx4-/- animals are viable and
fertile, with no apparent developmental defects.

Fbx4+/- and Fbx4-/- mice are tumor prone.
Multiple tissues harvested from young (1-2 month old) animals were assessed for
cyclin D1 and Fbx4 expression. Importantly, targeting exon 2 results in complete loss of
Fbx4 protein expression. Among the tissues examined, cyclin D1 protein accumulation
was noted in the mammary gland, lung, thymus and spleen (Figure 3.2A-D). Increased
cyclin D1 accumulation was also observed in both Fbx4+/- and Fbx4-/- primary MEFs
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(Figure 3.2E). RT-PCR analysis revealed equivalent levels of cyclin D1 message in
Fbx4+/+, Fbx4+/-, and Fbx4-/- MEFs, suggesting that protein accumulation occurs at the
post-translational level (Figure 3.2F).
Given the observed cyclin D1 accumulation in normal tissues derived from
Fbx4+/- and Fbx4-/- mice, we interrogated whether Fbx4+/- and Fbx4-/- mice develop
spontaneous tumors with increasing age. We monitored Fbx4+/+, Fbx4+/-, and Fbx4-/- mice
for up to 24 months and observed significant spontaneous tumor formation in both Fbx4+/and Fbx4-/- mice (Figure 3.3A). Fbx4+/- and Fbx4-/- mice exhibit tumors of lymphoblastic
lineage, frequent intense myeloid proliferation resulting from severe extramedullary
hematopoiesis, and early myeloid malignancy (Table 2). These mice develop large cell
lymphomas, as confirmed by flow cytometric and immunohistochemical analysis.
Additionally, dendritic cell tumors/histiocytic sarcomas of the spleen, thymus and
intestinal wall/mesentery, liver hemangiomas and hepatocellular carcinoma, and tumors
of the mammary and uterine epithelium were observed (Table 2). Fbx4+/- and Fbx4-/- mice
succumb to significant tumor burden with a mean survival of 23 months (Figure 3.3A).
Importantly, 60.6 percent and 64.3 percent of Fbx4+/- and Fbx4-/- mice, respectively
exhibit significant pathology before 24 months of age, highlighting the robust penetrance
of these phenotypes.
To examine whether tumorigenesis in Fbx4+/- mice was due to haploinsufficiency
or loss of heterozygosity (LOH), Fbx4 protein expression was analyzed in representative
tumor samples. Immunoblot analyses revealed that Fbx4+/- tumors and pre-malignant
tissues retain Fbx4 expression, albeit an approximate fifty percent reduction in expression
compared to wild type, suggesting that Fbx4 dosage is an important determinant in
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malignant transformation (Figure 3.3B). Consistent with this observation, one wild type
age matched control mouse exhibited severe extramedullary hematopoiesis, a phenotype
typically observed in Fbx4+/- and Fbx4-/- mice; strikingly, immunoblot analysis revealed
significant Fbx4 downregulation in this spleen.
Since normal and pre-malignant Fbx4+/- and Fbx4-/- tissues exhibit cyclin D1
protein accumulation, we ascertained whether cyclin D1 protein expression is elevated in
the various tumors. Consistently, elevated cyclin D1 protein was apparent in a majority of
lymphomas originating in the mesenteric node of both Fbx4+/- and Fbx4-/- mice and in
livers exhibiting lymphoma infiltrates or hepatocellular carcinoma (Figure 3.4A, B).
Furthermore, intestinal histiocytic sarcomas and mesenteric node lymphomas exhibit
nuclear cyclin D1 accumulation, correlating with increased proliferation as evidenced by
Ki-67 staining (Figure 3.4C).

Fbx4 deletion promotes cyclin D1 stabilization and nuclear accumulation.
To dissect the molecular mechanism underlying neoplastic transformation in
Fbx4+/- and Fbx4-/- mice, we prepared MEFs from Fbx4+/+, Fbx4+/-, and Fbx4-/- embryos
and examined cell proliferation and cyclin D1 accumulation. Primary Fbx4+/- and Fbx4-/MEFs exhibit cyclin D1 stabilization in S-phase, with significantly increased cyclin D1
half-life (Figure 3.5A). Importantly, cyclin D1 stabilization correlates with its robust
nuclear accumulation in primary MEFs (Figure 3.5B). Consistent with cyclin D1
deregulation in the absence of Fbx4, early passage primary MEFs also exhibit an
increased rate of proliferation compared to wild type MEFs (Figure 3.5C).
Subsequently, we determined whether cyclin D1 protein is stabilized throughout
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S-phase in Fbx4-/- cells. Primary early-passage MEFs were immortalized with p19Arf
shRNA, allowing extended culture and effective synchronization, and cyclin D1 levels
were assessed across late G1 through mid S-phase. In Fbx4+/+ cells, cyclin D1 is rapidly
degraded following the G1/S transition; conversely, cyclin D1 protein is elevated,
reflecting increased stability, through S-phase in Fbx4-/- cells (Figure 3.5D). Furthermore,
threonine 286 phosphorylated (pT286) cyclin D1 accumulates in Fbx4-/- cells, indicating
defective turnover of this short-lived cyclin D1 modification (Figure 3.5E). We also
determined whether cyclin D1 S-phase ubiquitylation requires Fbx4. Wild type and null
cells were synchronized and stimulated to enter S-phase with serum-derived growth
factors; cells were treated with the proteasome inhibitor MG-132 to allow accumulation
of poly-ubiquitylated proteins, and cyclin D1 was immunopurified. Immunoblot analysis
revealed markedly reduced cyclin D1 polyubiquitylation in Fbx4-/- cells compared to
Fbx4+/+ controls, suggesting that impaired cyclin D1 ubiquitylation/degradation drives
nuclear cyclin D1 accumulation in Fbx4-/- cells (Figure 3.5F).

Enhanced proliferation is antagonized by DNA damage in Fbx4-/- MEFs.
Primary MEFs were maintained on a 3T9 passage protocol to evaluate the onset
of cellular senescence. While early passage Fbx4-/- MEFs initially accumulate to a higher
density, proliferation is dramatically reduced between passage 6-7, compared to the
gradual proliferative decline observed in Fbx4+/+ MEFs (Figure 3.6A). Importantly, both
wild type and null MEFs exhibit similar patterns of senescence-associated p19Arf and
p16Ink4a induction, and p19Arf shRNA facilitates immortalization both wild type and null
cells with similar kinetics, suggesting that reduced proliferation in primary null cells may
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result from alternative mechanisms such as DNA damage (Figure 3.6B, C) Significantly,
Fbx4-/- MEFs accumulate H2AX, as well as p53 and its downstream target, p21Cip1,
consistent with induction of the DNA damage checkpoint in later passages (Figure 3.6 DE, Figure 3.5D). Fbx4-/- cells also accumulate DSB-associated nuclear foci (Figure 3.6F).
Previous studies established that primary MEF proliferation under atmospheric oxygen is
limited by oxidative DNA damage, despite maintenance of long telomeres (Parrinello et
al., 2003). Importantly, Fbx4-/- MEFs display markers of DNA damage earlier than
Fbx4+/+ counterparts, and DNA damage in Fbx4-/- MEFs cannot be rescued by culture
under physiological oxygen (3% O2, Figure 3.6F), providing evidence that oxidative
stress alone does not account for DNA damage accumulation in Fbx4-/- MEFs.
Knockdown of p19Arf bypasses cellular senescence, allowing immortalization of
Fbx4+/+ and Fbx4-/- MEFs; such immortalized cells do not exhibit proliferative defects
(Figure 3.6C). Next, we assessed whether immortalized Fbx4+/+ and Fbx4-/- cells are
selectively sensitive to S-phase DNA damage. Fbx4+/+ and Fbx4-/- cells were
synchronized in S-phase, pulsed with 2mM HU for 2 hours, followed by HU washout,
incubation in complete media, and treatment with colcemid to arrest cells in metaphase.
Metaphase spreads prepared from Fbx4-/- cells exhibited a significant increase in
chromosome alterations compared to wild type controls (Figure 3.6G).
Previous work established that nuclear cyclin D1 accumulation promotes DNA rereplication during S-phase and continued DNA replication in the presence of S-phase
DNA damage, thereby facilitating genomic instability; these phenotypes are driven by
nuclear cyclin D1/CDK4-mediated CUL4 repression and CDT1 stabilization (Aggarwal
et al., 2007; Pontano et al., 2008). Consistent with these findings, CDT1 protein is
72

stabilized throughout S-phase in Fbx4-/- cells, with a concomitant reduction in CUL4A
expression (Figure 3.7A). Collectively, these data reveal that loss of Fbx4 triggers
nuclear cyclin D1 accumulation, DNA damage checkpoint activation, and ultimately
genomic instability.
Our data revealed attenuated cyclin D1 turnover in primary S-phase Fbx4-/- MEFs
(Figure 3.5A); furthermore, cyclin D1 degradation in response to S-phase DNA damage
is impaired in Fbx4-/- MEFs (Figure 3.7B), suggesting that Fbx4 is a critical mediator of
cyclin D1 destruction in unperturbed S-phase progression and following S-phase DNA
damage. Since GSK3 phosphorylates Fbx4, triggering ligase dimerization and activation
(Barbash et al., 2008), and GSK3 activity increases following S-phase DNA damage
(Lee et al., 2007; Pontano et al., 2008), we next ascertained whether Fbx4
phosphorylation and ligase activity are regulated by S-phase DNA damage. Treatment of
S-phase cells with ionizing radiation enhanced Fbx4 phosphorylation, concomitant with
elevated cyclin D1 phosphorylation (Figure 3.7C). Moreover, SCFFbx4 E3 ubiquitin ligase
activity toward cyclin D1 substrate in vitro is markedly increased when SCFFbx4
complexes are purified from -irradiated S-phase NIH 3T3 cells (Figure 3.7D). Together,
these data indicate that both phosphorylation-dependent cyclin D1 nuclear export, as well
as phosphorylation-dependent Fbx4 ligase activation synergize to promote cyclin D1
ubiquitylation following S-phase DNA damage, thereby preserving genome integrity.

Fbx4 loss cooperates with RasV12 in vitro.
The data provided demonstrate that Fbx4+/- and Fbx4-/- mice are tumor prone and
this correlates with deregulation of cyclin D1 accumulation.
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Because cyclin D1

overexpression cooperates with Ras to induce cellular transformation, we considered
whether Fbx4+/- or Fbx4-/- primary MEFs were susceptible to transformation induced by
oncogenic Ha-Ras(V12). Infection of early passage MEFs with retroviruses harboring
empty vector or oncogenic Ha-Ras(V12) resulted in foci formation in both Fbx4+/- and
Fbx4-/- MEFs, but not Fbx4+/+ MEFs (Figure 3.8A). While overexpression of wild type
cyclin D1 alone does not promote cell transformation or tumorigenesis in immune
compromised mice (Quelle et al., 1993), expression of cyclin D1 mutants that are stably
retained in the nucleus is oncogenic (Alt et al., 2000). To determine whether Fbx4 loss
and subsequent nuclear accumulation of endogenous cyclin D1 promotes cellular
transformation, we examined the capacity of multiple p19ArfshRNA-immortalized cell
lines to form foci in vitro. While immortalized Fbx4+/+ cells were refractory to
spontaneous transformation, Fbx4+/-, and to a greater extent, Fbx4-/- cells readily exhibited
spontaneous transformation (Figure 3.8B), suggesting that Fbx4 plays a requisite role in
suppressing tumorigenesis in vivo and cellular transformation in vitro.

74

DISCUSSION
The SCFFbx4 E3 ubiquitin ligase has been previously implicated in regulating
cyclin D1 turnover in cell culture models. Further work revealed a significant role for
Fbx4 function in maintaining cell integrity, highlighted by the relative frequency of
mutations that impair its biochemical activity in human tumors. Such mutations occur in
a hemizygous manner, consistent with the notion that reduced Fbx4 expression is
sufficient for cyclin D1 deregulation and neoplastic transformation (Barbash et al., 2008).
While these lines of evidence suggest that Fbx4 may function as a tumor suppressor,
genetic studies in vivo have not been performed to directly address this question. We
have interrogated Fbx4-dependent tumor suppression in vivo, through targeted disruption
of murine Fbx4. Our data reveal that loss of Fbx4 in mice does not impact viability or
development; however, a significant increase in age-associated malignancy was observed
in Fbx4+/- and Fbx4-/- mice compared to wild type. Furthermore, Fbx4 loss in MEFs
triggered cyclin D1 stabilization and nuclear accumulation, and aberrant cyclin D1
regulation in the absence of Fbx4 drives the accumulation of DNA damage and
subsequent genomic instability, a hallmark of neoplastic transformation. Consistently,
loss of Fbx4 facilitates cell transformation in vitro, further emphasizing the tumor
suppressive properties of Fbx4.

Fbx4 is a tumor suppressor.
Both Fbx4+/- and Fbx4-/- aged mice commonly develop lymphoid malignancies
involving the mesenteric node, spleen, liver, and intestine, as well as histiocytic sarcomas
of the intestinal wall and mesentery, dendritic cell tumors of the spleen and thymus, early
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myeloid malignancies, and mammary, hepatocellular, and uterine carcinomas occurring
at lesser frequencies. Fbx4+/- tumors retain Fbx4 expression, consistent with human
cancer data revealing hemizygous Fbx4 mutations (Barbash et al., 2008). In addition,
Fbx4+/- and Fbx4-/- MEFs are susceptible to single step, Ras-mediated transformation,
supporting the notion that Fbx4 functions as a haploinsufficient tumor suppressor. While
an elevation in cyclin D1 protein in Fbx4+/- and Fbx4-/- in epithelial tissue might be
anticipated, the increased cyclin D1 expression is in lymphocytes, which typically do not
express cyclin D1, and lymphoid tumors were indeed enlightening. These results support
a requisite role for posttranslational degradation as a means to limit cyclin D1
accumulation in normal lymphoid tissue, highlighting the tumor suppressive function of
Fbx4 in this tissue. Interestingly, not all tissues exhibiting elevated cyclin D1 develop
neoplastic lesions; for example cyclin D1 is elevated in normal Fbx4+/- and Fbx4-/- lung
tissue; however, spontaneous lung adenocarcinomas were not observed. This raises the
possibility that development in the absence of Fbx4 results in compensatory pathways for
cyclin D1/CDK4 regulation, ultimately antagonizing nuclear function when Fbx4mediated degradation is impaired.
Fbx4+/- and Fbx4-/- mice develop tumors with a protracted latency that is
comparable to pituitary tumors observed in p18Ink4c-/- mice, sarcomas in p15Ink4b-/- mice,
and B-cell lymphomas, lung adenocarcinomas, and hepatocellular carcinomas in
U19/Eaf2-/- mice (Latres et al., 2000; Xiao et al., 2008). Although tumors arise in aged
mice, it is important to note that this is a remarkably penetrant phenotype, with 38
percent of Fbx4+/- and Fbx4-/- mice exhibiting substantial lymphoma burden and 23.4
percent exhibiting EMH before 24 months of age. Furthermore, the frequent incidence of
76

EMH and associated early myeloid malignancy suggests bone marrow failure, and it is of
interest to assess the role of Fbx4 in hematopoietic development and bone marrow
function in future work.

Loss of Fbx4 promotes cyclin D1 nuclear accumulation and DNA damage.
Previous work has linked nuclear cyclin D1 accumulation with tumorigenesis
(Gladden et al., 2006; Lin et al., 2007). However, the rare incidence of cyclin D1
mutations that impair nuclear export and cytoplasmic degradation suggests that other
components of the cyclin D1 regulatory machinery, such as Fbx4, are targeted during
neoplastic transformation. Consistent with this notion, we observed a substantial
extension of cyclin D1 half-life in S-phase Fbx4-/- MEFs, with a moderate, yet significant,
increase in cellular proliferation and substantial nuclear cyclin D1 accumulation.
Importantly, accumulating evidence suggests that cyclin D1 nuclear localization during
S-phase, not simply overexpression, underlies its oncogenic function (Aggarwal et al.,
2007; Aggarwal et al., 2010; Gladden et al., 2006; Lin et al., 2007).
Consistent with the aforementioned nuclear cyclin D1 phenotype, the initial
proliferative advantage observed in Fbx4-/- MEFs dramatically decreases in later
passages, suggesting that cells either activate a senescence program prematurely, or
decrease proliferation as a consequence of DNA damage and/or additional stress
responses. Our data support the generation of DNA damage, as DNA damage checkpoint
activation is clearly evident in passage 3-5 MEFs. Importantly, DNA damage observed in
Fbx4-/- MEFs is not simply due to oxidative stress, as growth under physiological (3%) O2
tension does not reduce DNA damage. In addition, DNA damage is not likely to result
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from stabilization of the other known Fbx4 substrate, Trf1, given that telomere uncapping
effects of Trf1 stabilization would take many generations, due to the extremely long
telomeres observed in most laboratory mouse lines (Lee et al., 2006). Nuclear cyclin D1
retention during S-phase promotes DNA re-replication and subsequent DNA damage
checkpoint activation; mechanistically, nuclear cyclin D1/CDK4 kinase activity is
necessary for elevated histone arginine methylation at the CUL4 promoters, CUL4
repression, and consequent stabilization of the replication factor CDT1 (Aggarwal et al.,
2007; Aggarwal et al.). In fact, tumors arising in Fbx4+/- and Fbx4-/- mice exhibit a
dramatic increase in histone 4 arginine 3 symmetric di-methylation (H4R3, Figure 3.4A),
and Fbx4-/- MEFs exhibit CDT1 stabilization in S-phase, with a concomitant reduction in
CUL4 levels, supporting the notion that CDT1 stabilization downstream of nuclear cyclin
D1/CDK4 activity drives DNA damage accumulation.
Our previous and current data reveal a tightly regulated mechanistic program for
cyclin D1 control in S-phase and following DNA damage. Fbx4 serine 12
phosphorylation, an event preceding ligase dimerization and activation, ensures an
increased rate of cyclin D1 ubiquitylation following the G1/S transition. Intriguingly,
both nuclear cyclin D1 T286 and cytoplasmic Fbx4 S12 are phosphorylated by GSK3 at
this phase of the cell cycle, highlighting the dual regulatory role posttranslational
modifications play in coordinating timely cyclin D1 destruction (Barbash et al., 2008;
Diehl et al., 1998). Therefore, it is not surprising that both cyclin D1 T286 and Fbx4 S12
phosphorylation events are induced above basal levels following S-phase DNA damage,
thereby facilitating increased ubiquitin ligase activity toward cyclin D1 substrate (Figure
3.7C, D). Considering that nuclear cyclin D1 accumulation promotes DNA re-replication
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and checkpoint activation, and that impaired cyclin D1 degradation in response to Sphase DNA damage drives genomic instability, loss or functional inactivation of Fbx4
provides oncogenic insults necessary for neoplastic transformation.
Collectively, our current work supports the notion that Fbx4 expression is
essential for cell homeostasis in somatic cells. Fbx4 ablation predisposes mice to multiple
tumor phenotypes, with concomitant cyclin D1 deregulation and nuclear accumulation.
Furthermore, our data suggest that Fbx4 status is an important determinant of neoplastic
potential in cells harboring wild type cyclin D1 overexpression, functioning as a
haploinsufficient tumor suppressor. Identification of novel Fbx4 substrates will elucidate
additional signaling pathways contributing to the neoplastic phenotype in Fbx4-/- animals
functioning in concert with cyclin D1, and future development of Fbx4 conditionallydeficient mice will enable Fbx4 ablation in various adult tissues, mirroring the somatic
inactivating mutations observed in human cancers.
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CHAPTER IV:
NUCLEAR CYCLIN D1/CDK4 KINASE REGULATES CUL4 EXPRESSION AND
TRIGGERS NEOPLASTIC GROWTH VIA ACTIVATION OF THE PRMT5
METHYLTRANSFERASE

This chapter has been published as a co-first author article with Dr. Priya Aggarwal in:
Cancer Cell 18 (4): 329-340. October 19, 2010.
Reprinted by permission from Elsevier
License Number: 2661040720840
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SUMMARY
Cyclin D1 elicits transcriptional effects through inactivation of the retinoblastoma
protein and direct association with transcriptional regulators. The current work reveals a
molecular relationship between cyclin D1/CDK4 kinase and protein arginine
methyltransferase 5 (PRMT5), an enzyme associated with histone methylation and
transcriptional repression. Primary tumors of a mouse lymphoma model exhibit increased
PRMT5 methyltransferase activity and histone arginine methylation. Analyses
demonstrate that MEP50, a PRMT5 co-regulatory factor, is a CDK4 substrate, and
phosphorylation increases PRMT5/MEP50 activity. Increased PRMT5 activity mediates
key events associated with cyclin D1-dependent neoplastic growth, including CUL4
repression, CDT1 overexpression, and DNA re-replication. Importantly, human cancers
harboring mutations in Fbx4, the cyclin D1 E3 ligase, exhibit nuclear cyclin D1
accumulation and increased PRMT5 activity.
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INTRODUCTION
Cyclin D1, the allosteric regulator of CDK4 and CDK6, is an integral mediator of
growth factor-dependent G1-phase progression. Growth factor stimulation induces cyclin
D1 expression, association with CDK4 and nuclear accumulation during mid-G1; active
cyclin D1/CDK4 kinase catalyzes phosphorylation-dependent inactivation of the
retinoblastoma (RB) family proteins (Diehl, 2002). Following the G1/S transition, cyclin
D1 accumulation is opposed by Pro287-directed phosphorylation of threonine 286 (T286)
by glycogen synthase kinase 3 (GSK3), which promotes its nuclear export (Alt et al.,
2000). Cytoplasmic, phosphorylated cyclin D1 is polyubiquitylated by SCFFbx4 and
degraded by the 26S proteasome (Lin et al., 2006).
Overexpression of cyclin D1 occurs in numerous human malignancies including
carcinomas of the breast, esophagus, colon, and lung (Bani-Hani et al., 2000; Bartkova et
al., 1994a; Bartkova et al., 1995; Bartkova et al., 1994b; Gillett et al., 1994; Herman et
al., 1995; Hibberts et al., 1999; Hosokawa and Arnold, 1998; Hosokawa et al., 1999; Jin
et al., 2001). While overexpression of cyclin D1 is often observed, overexpression per se
is insufficient to drive spontaneous transformation. The primary cellular mechanism that
restricts cyclin D1/CDK4 activity is cytoplasmic, ubiquitin-mediated degradation of
cyclin D1 during S-phase.

Mutations that disrupt this event directly contribute to

neoplastic growth (Aggarwal et al., 2007; Alt et al., 2000; Barbash et al., 2008; Benzeno
et al., 2006; Lu et al., 2003). Specifically, inhibition of cyclin D1 proteolysis during Sphase via mutations within the cyclin D1 degron or inactivation of the cyclin D1 E3
ligase, Fbx4, triggers constitutive nuclear accumulation of active cyclin D1/CDK4
complexes which, in turn, disrupt temporal regulation of DNA replication, thereby
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contributing to neoplastic growth.

The disruption of S-phase fidelity reflects

accumulation of the replication licensing protein CDT1. Inappropriate CDT1 stabilization
is a result of nuclear cyclin D1/CDK4-dependent repression of CUL4A and CUL4B,
encoding scaffolding proteins for the E3 ligase that directs CDT1 degradation during Sphase (Aggarwal et al., 2007).
Numerous previous studies have linked cyclin D1 with transcriptional repression.
Current models focus on an intrinsic capacity of cyclin D1 to associate directly with
transcriptional regulators and either interfere with the recruitment of co-factors that direct
gene repression or conversely, facilitate co-activator recruitment as observed in the
collaboration between cAMP signaling and cyclin D1 in the activation of estrogen
receptor (ER)-mediated transcription in mammary epithelial cells (Lamb et al., 2000).
The strongest evidence for cyclin D1 directly contributing to the regulation of gene
expression stems from recent work utilizing genome-wide chromatin immune
precipitation to identify promoters occupied by cyclin D1 (Bienvenu et al., 2010).
A common theme throughout this previous work is that cyclin D1 modulates gene
expression in a kinase-independent manner.

However, transcriptional repression of

CUL4A and CUL4B by cyclin D1 requires S-phase accumulation of catalytically active
cyclin D1/CDK4 (Aggarwal et al., 2007). The current study dissects the molecular
mechanism of CUL4A/B transcriptional regulation by cyclin D1 and its contribution to
nuclear cyclin D1-driven neoplastic growth.
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RESULTS
Association of the PRMT5/MEP50 methyltransferase with cyclin D1T286A/CDK4.
To decipher mechanisms of nuclear cyclin D1-driven neoplasia, we
immunopurified cyclin D1T286A complexes from tumors derived from Eμ-D1T286A
transgenic mice (Gladden et al., 2006) and identified co-purifying proteins by mass
spectrometry (data not shown).

Given previous reports linking cyclin D1 with

transcriptional repression, we were intrigued by co-purification of PRMT5, a Type II
methyltransferase, along with MEP50, a WD40 repeat containing protein that contributes
to PRMT5 activity and substrate recruitment (Krause et al., 2007). Co-precipitation of
cyclin D1T286A, CDK4, MEP50 and PRMT5 from B-cell tumors confirmed the
interaction (Figure 4.1A-B). To ascertain the existence of this complex in human cancer
cells, we used TE3 and TE7 cell lines that harbor cyclin D1P287A (Benzeno et al., 2006).
Cyclin D1P287A is refractory to GSK3-dependent phosphorylation and is stabilized in
the nucleus, analogous to D1T286A. Consistent with the above results, we observed coprecipitation of cyclin D1P287A along with MEP50, PRMT5, and CDK4 (Figure 4.1C).
Association of cyclin D1T286A with PRMT5 in concert with previous work
demonstrating that cyclin D1T286A reduces CUL4A/B expression in a CDK4-dependent
manner (Aggarwal et al., 2007) suggested a potential regulatory relationship involving
cyclin D1T286A and chromatin modifying proteins. To interrogate this putative
relationship, we co-expressed Myc-PRMT5 together with CDK4 and either wild type
cyclin D1 or D1T286A in HeLa cells. Following synchronization at the G1/S boundary
and release into S-phase, complexes were immune precipitated and associated proteins
identified by immunoblot. Cyclin D1T286A was enriched in PRMT5 complexes at the
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G1/S boundary and declined as cells progressed through S-phase (Figures 4.1D). In
contrast, low levels of wild type cyclin D1 were associated with PRMT5, with no obvious
enrichment. The reduced binding of wild type cyclin D1 reflects both its low abundance,
due to proteolysis during S-phase, and cytoplasmic localization of the remaining protein
(Alt et al., 2000; Barbash et al., 2008).
To determine whether known components of chromatin remodeling complexes
were also present in the cyclin D1T286A-PRMT5 complex, we performed a two-step
affinity purification of this complex.

Initially, Flag-D1T286A-containing complexes

were collected from pooled tumor lysates by M2-affinity chromatography, which was
used to isolate flag-tagged cyclin D1. Complexes were eluted with flag peptide then reprecipitated with PRMT5 antibodies. In addition to the expected components (cyclin
D1T286A, CDK4, PRMT5, MEP50) we also noted Brg1 (Figure 4.1E). Importantly,
these complexes do not contain RB, PRMT5-related PRMT1 and PRMT7, mSin3a (a
component of large multi-subunit histone deacetylase (HDAC) co-repressor complexes),
or Mi2 (a nucleosome remodeling and HDAC complex component, Figure 4.1E). This
result reveals the existence of a cyclin D1T286A, CDK4, MEP50, PRMT5 and Brg1
complex. Consistently, we also noted co-precipitation of Brg1 with endogenous cyclin
D1P287A in TE3 and TE7 cells (Figure 4.1C). Consistently, size exclusion
chromatography revealed co-fractionation of cyclin D1T286A, CDK4, PRMT5, MEP50,
and Brg1 in murine lymphomas (data not shown).

PRMT5/MEP50 mediates cyclin D1T286A/CDK4-dependent CUL4A/B loss and
CDT1 stabilization.
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Because PRMT5-dependent di-methylation of histone H3 arginine 8 (H3R8) and
histone H4 arginine 3 (H4R3) is associated with transcriptional repression (Pal et al.,
2004), we considered whether PRMT5 would mediate cyclin D1T286A/CDK4dependent repression of CUL4A/B. We first used the general methyltransferase inhibitor
5’ Deoxy-5”-methyl-thioadenosine (MTA) (Hou et al., 2008; Iwasaki and Yada, 2007),
following identification of a concentration that inhibited H4R3 methylation but not H3K4
methylation (Figure 4.2A). As previously observed, expression of catalytically active
cyclin D1T286A/CDK4 resulted in the maintenance of CDT1 and loss of CUL4A/B
proteins and mRNAs specifically during S-phase (Figures 4.2B-D). Treatment with
100mM MTA restored CUL4A/B proteins and mRNAs and triggered CDT1 degradation
during S-phase (Figure 4.2B). A similar restoration of CUL4A/B was observed with
another PRMT inhibitor, AMI-1 (Cheng et al., 2004) (data not shown).
As an independent assessment of PRMT5 function, we utilized siRNA directed at
PRMT5 or MEP50. Knockdown of PRMT5 (Figures 4.2E; G-H) or MEP50 (data not
shown) restored expression of CUL4A/B and CDT1 loss during S-phase. Knockdown of
PRMT5 also reduced H4R3 and H3R8 methylation but did not change levels of PRMT1,
2, and 7 (Figure 4.2E). We confirmed previous observations that regulation of CUL4 and
CDT1 requires the kinase activity of CDK4 as expression of a kinase defective mutant,
CDK4(K35M), does not support cyclin D1T286A-dependent CUL4 loss and eliminates
the impact of PRMT5 knockdown (Figure 4.2F).
Since attenuation of PRMT5 relieves CUL4 repression, we questioned whether
cyclin D1T286A regulates HDAC activity, contributing to CUL4 repression.
Synchronized HeLa cells were treated with the HDAC inhibitors sodium butyrate,
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trichostatin A and nicotinamide; each inhibitor increased CUL4 expression independent
of cyclin D1T286A. Furthermore, acetylation of histone H3 and H4 within the CUL4A
promoter and CUL4B promoter (data not shown) was not influenced by cyclin D1T286A,
suggesting that HDAC activity is not coordinately regulated with histone arginine
methylation by cyclin D1T286A/CDK4 at the CUL4 promoters.

Cyclin D1T286A/CDK4 kinase directs increased PRMT5 activity and PRMT5dependent methylation of CUL4 promoters.
If PRMT5 mediates the action of cyclin D1T286A/CDK4 in vivo, we reasoned
that increased H3R8 di-methylation, a PRMT5-specific mark (Pal et al., 2004), should be
apparent in tumors derived from Eμ-D1T286A mice. Methylated H3R8 was elevated in
tumors compared to non-transgenic controls (Figure 4.3A-B). Given the increase in total
H4R3/H3R8 methylation, we determined whether there was an increase in H4R3/H3R8
methylation on the proximal CUL4A/B promoter regions by ChIP using antibodies
detecting di-methylated H4R3 and di-methylated H3R8 (Primer design, Figure 4.3C). We
observed an ~2-3 fold increase in methylation of both H4R3 and H3R8 at the proximal
promoter regions (~500bp upstream of the first coding exon) of CUL4B (Figure 4.3D) in
the presence of cyclin D1T286A/CDK4 as compared to cyclin D1/CDK4 or
untransfected controls in S-phase HeLa cells. No enrichment was detected with primers
directed to regions corresponding to 1000bp upstream (data not shown) or ~5000bp
upstream of first coding exon of CUL4B (control/blue bars Figure 4.3D). Using PRMT5
specific antibodies for ChIP, we noted PRMT5 occupancy of the same region of the
CUL4 promoters (Figure 4.3E).

Critically, siRNA-mediated knockdown of PRMT5
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resulted in significant attenuation of cyclin D1T286A/CDK4 dependent H4R3/H3R8
methylation at CUL4A/B promoter regions during S-phase (Figure 4.3F). In agreement
with cyclin D1T286A directly contributing to increased PRMT5 activity, cyclin
D1T286A occupancy of both Cul4A/B promoters was observed in cyclin D1T286A
expressing primary murine lymphoma cells (Figure 4.3G, data not shown).
To determine whether increased methylation of histones reflected increased
PRMT5 activity, we assessed methyltransferase activity of PRMT5 immune-purified
from control or tumor-burden spleens and found that four of six tumors exhibited an
increase in PRMT5 activity (Figure 4.4A). While PRMT5 levels are increased in cyclin
D1T286A tumors, it does not appear sufficient to account for the dramatic increase in
PRMT5 catalysis observed. To more directly determine whether this increase reflects the
action of cyclin D1T286A/CDK4, we reconstituted this pathway in HeLa cells.
Consistently, PRMT5 isolated from S-phase cells expressing cyclin D1T286A exhibited
enhanced methyltransferase activity; a small but significant increase was also observed in
cells overexpressing wild type cyclin D1/CDK4 (Figure 4.4B). Furthermore, we observed
increased methylation of recombinant H3R8 in vitro (Figure 4.4C).

Phosphorylation of MEP50 by cyclin D1T286A/CDK4 in vitro and in vivo.
We next considered whether either MEP50 or PRMT5 might be a cyclin
D1/CDK4 substrate. PRMT5/MEP50 complexes were precipitated from HeLa cells
expressing cyclin D1 or cyclin D1T286A along with either CDK4 or CDK4(K35M) with
a MEP50 antibody. Upon immunoblotting with an antibody detecting phosphorylated
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serine or threonine when either residue is followed by a proline, we noted a band in cells
expressing cyclin D1T286A/CDK4 that migrated with the expected mobility of MEP50
(Figure 4.5A, noted by arrow). No such band was apparent in cyclin D1 expressing cells
or in cyclin D1T286A/CDK4(K35M) expressing cells. In addition, we did not detect any
apparent p-SP/TP signal corresponding to PRMT5.
MEP50 contains four putative CDK phosphorylation sites: T5, S176, S264, and
S306 (Figure 4.5B). Consistent with MEP50 being a direct substrate, recombinant
MEP50 was phosphorylated by cyclin D1/CDK4 and D1T286A/CDK4 in vitro (Figure
4.5C). To identify phosphorylated residues, recombinant MEP50 was phosphorylated in
vitro with purified cyclin D1T286A/CDK4 and subjected to mass spectrometry; we also
affinity purified MEP50 from cells co-expressing cyclin D1T286A/CDK4 for the same
analysis. Both approaches revealed phosphorylation of MEP50 at threonine 5 (T5, data
not shown). We generated recombinant MEP50 proteins harboring alanine substitutions
at all four putative CDK phosphorylation sites and used these as substrates. Mutation of
T5 dramatically reduced phosphate incorporation; mutation of S264 and S306 also
resulted in a moderate reduction while S176A had no apparent effect (Figure 4.5D).
If

CUL4

repression

and

CDT1

stabilization

depends

upon

MEP50

phosphorylation by cyclin D1T286A/CDK4, we reasoned that overexpression of key
non-phosphorylatable MEP50 mutants should be inhibitory. Indeed, expression of myctagged MEP50-T5A and to a lesser degree MEP50-S264A interfered with cyclin
D1T286A-dependent CDT1 stabilization and CUL4 loss during S-phase (Figure 4.5E).
Collectively, these results reveal that MEP50 is a CDK4 substrate and that
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phosphorylation of MEP50 predominantly on T5 dominantly mediates downstream
function.

Cyclin D1T286A/CDK4 regulates PRMT5 methyltransferase activity via MEP50
phosphorylation.
To determine whether phosphorylation of MEP50 can directly regulate PRMT5
methyltransferase activity independent of association with high molecular weight
chromatin remodeling complexes, coupled in vitro kinase/methyltransferase reactions
were performed with purified recombinant PRMT5/MEP50 produced in Sf9 cells.
PRMT5-dependent methyltransferase activity was increased following a kinase reaction
with

purified

cyclin

D1T286A/CDK4

(Figure

4.6A).

Additionally,

increased

PRMT5/MEP50 SAM-dependent methyltransferase activity directed towards histone H4
was readily apparent following incubation of PRMT5/MEP50 complexes purified from
HeLa cells with cyclin D1T286A/CDK4 and to a lesser degree with cyclin D1/CDK4
(Figure 4.6B). To evaluate the role of MEP50 phosphorylation, we expressed either wild
type MEP50 or mutant MEP50 alleles in cells treated with MEP50 siRNA. Expression of
MEP50-T5A maintained basal methyltransferase activity in vitro, but was refractory to
the CDK4-dependent increase of PRMT5 activation (Figure 4.6C). Serine-264 to alanine
substitution also attenuated the response to cyclin D1T286A/CDK4 whereas alanine
substitution at 176/306 was without influence. These results demonstrate that cyclin
D1/CDK4 can increase histone methyltransferase activity of PRMT5/MEP50 through
phosphorylation of T5 and perhaps through S264.
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PRMT5/MEP50 mediates cyclin D1T286A-dependent re-replication, transformation
and survival of cyclin D1T286A expressing lymphoma cells.
Cyclin D1T286A/CDK4 expression induces re-replication in a CDT1-dependent
fashion (Aggarwal et al., 2007). If PRMT5/MEP50 mediates re-replication, knockdown
of PRMT5 should be inhibitory. Consistent with this hypothesis, we observed a dramatic
reduction of >4N population from 26.8% to 2.28% with PRMT5 knockdown in
T286A/CDK4/CDT1 transfected HeLa cells (Figure 4.7A-B).
We next determined whether PRMT5 mediates cyclin D1T286A-dependent
transformation by knockdown of PRMT5 in murine fibroblasts, concurrent with
expression of oncogenic RasV12 and cyclin D1T286A. Indeed, while co-transfection of
both RasV12 and cyclin D1T286A induced focus formation (Figure 4.7C), foci number
was reduced by 50% following knockdown of PRMT5. Importantly, PRMT5 knockdown
was not accompanied by cell cycle arrest, suggesting that foci reduction is not a
consequence of cell cycle arrest (data not shown). In addition, PRMT5 knockdown did
not significantly attenuate transformation mediated by Ras plus c-Myc, suggesting
mechanistic specificity between PRMT5-dependent methyltransferase activity and
constitutively nuclear cyclin D1 (Figure 4.7C).
To investigate therapeutic potential of targeting PRMT5, we determined whether
inhibition of PRMT5 would compromise survival of primary Em-D1T286A lymphoma
cells ex vivo. Because we were unable to efficiently introduce siRNA into these primary
tumor cells, we utilized AMI-1. AMI-1 treatment increased death of tumor cells relative
to normal controls (Figure 4.7D). In addition, treatment of primary lymphoma cells with
MTA also triggered increased cell death relative to untreated tumor cells or MTA treated
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control lymphocytes (data not shown). Together, these observations suggest that PRMT5
plays an important role in promoting cyclin D1T286A/CDK4-dependent DNA rereplication, cell transformation and survival of cells harboring constitutively active cyclin
D1/CDK4.
To examine the role of MEP50 phosphorylation in cyclin D1T286A-dependent
transformation, wild type or phosphorylation-deficient T5A or S264A mutant MEP50
was co-expressed with RasV12 and cyclin D1T286A in NIH3T3 cells. Compared to wild
type MEP50, expression of the T5A or S264A MEP50 mutant significantly reduced foci
number, suggesting that phosphorylation of MEP50 and subsequent increase in PRMT5
activity is a driving force for cellular transformation in the presence of cyclin D1T286A
(Figure 4.7E).

Fbx4 inactivation promotes increased PRMT5-dependent histone methylation.
While mutations directly targeting cyclin D1 do occur in human cancer (Benzeno
et al., 2006), they occur infrequently relative to inactivation of the cyclin D1 E3 ligase
(Barbash et al., 2008). Because inactivation of Fbx4 also drives nuclear accumulation of
cyclin D1 kinase during S-phase, we postulated that Fbx4 loss should also impact
PRMT5 function. We initially assessed this hypothesis in NIH 3T3 cells harboring Fbx4
shRNA (Lin et al., 2006). Fbx4 knockdown increased cyclin D1 and CDT1 and decreased
CUL4A/B; critically, the level of H4R3 methylation was dramatically increased (Figure
4.8A). Previous work identified esophageal tumors harboring inactivating mutations in
Fbx4 that resulted in strong cyclin D1 overexpression (Barbash et al., 2008). We chose
these same tumors to ascertain whether loss of Fbx4 function and overexpression of wild
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type

cyclin

D1

kinase

also

correlated

with

increased

H4R3

methylation.

Immunohistochemical staining on tumor sections revealed a marked increase in H4R3
methylation relative to an esophageal tumor harboring wild type Fbx4 or normal
esophageal epithelium (Figure 4.8B). Because our analysis was restricted to tumors with
known Fbx4 mutations and tissue availability for IHC (n=4), our analysis did not achieve
statistical significance. To support this analysis, we analyzed an esophageal tumor cell
line harboring a mutant Fbx4, Fbx4(S8R), TE10 cell line) (Barbash et al., 2008) and
another expressing both wild type Fbx4 and cyclin D1 (TE15) and found that inactive
Fbx4 correlates with increased CDT1 and methylated H4R3 (Figure 4.8C). Together,
these observations demonstrate that stabilized nuclear cyclin D1 resulting from either
cyclin D1 mutation or inactivation of Fbx4 results in increased PRMT5-dependent
histone methylation.
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DISCUSSION
Cyclin D1 is subject to intricate post-translational control to ensure its temporal
regulation. Cyclin D1 nuclear export followed by Fbx4-dependent ubiquitylation and
degradation during S-phase are key features that serve to restrain nuclear cyclin
D1/CDK4 activity and ensure normal cell division (Alt et al., 2000; Benzeno et al., 2006;
Lin et al., 2006). Previous work revealed that aberrant nuclear accumulation of cyclin D1
during S-phase promotes transformation in vitro (Alt et al., 2000) and drives both B-cell
lymphomas and mammary carcinomas in mice (Gladden et al., 2006; Lin et al., 2008).
Molecular analysis of these tumors revealed a potential mechanism wherein the cyclin
D1-dependent kinase interferes with CUL4-dependent CDT1 proteolysis during S-phase
(Higa et al., 2006; Sansam et al., 2006), due to transcriptional repression of CUL4A and
CUL4B; the resulting overexpression of CDT1 during S-phase triggers DNA rereplication, enhancing genomic instability and the acquisition of fortuitous mutations
(Aggarwal et al., 2007). A significant feature of the regulatory pathway leading to loss of
CUL4 expression is the noted dependence upon cyclin D1/CDK4 activity. The current
work revealing that phosphorylation of MEP50 on T5 by cyclin D1T286A/CDK4
mediates PRMT5-dependent transcriptional repression provides key mechanistic insights
into the neoplastic activities of the cyclin D1/CDK4 enzyme.
While PRMT5/MEP50 was identified through affinity purification of D1T286A
complexes, it is the demonstration that MEP50 is a direct substrate for D-type cyclin
dependent kinase that contributes a key advance in our understanding of cyclin D1-driven
tumorigenesis. Phosphorylation of MEP50 on T5 by D1T286A/CDK4 is necessary and
sufficient to increase the intrinsic methyltransferase activity of PRMT5, resulting in
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increased H4R3/H3R8 methylation and repression of the CUL4A/B expression. Notably,
although we did not detect phosphorylation of S264 in vivo, mutation of S264 to alanine
in MEP50 reduced cyclin D1-dependent induction of PRMT5 activity, suggesting that
phosphorylation of this site may also contribute.

The fact that inhibition of

PRMT5/MEP50 activity by siRNA or overexpression of non-phosphorylatable MEP50
attenuates CUL4 repression is consistent with a model where PRMT5/MEP50 represents
a key molecular target of nuclear cyclin D1/CDK4 during S-phase (Figure 4.9).

Regulation of PRMT5 by the cyclin D1-dependent kinase
PRMT5 methylates arginines in multiple proteins including myelin basic protein
(Ghosh et al., 1988), SM proteins (Friesen et al., 2001) and p53 (Jansson et al., 2008).
However, it is PRMT5-dependent histone di-methylation that is associated with
transcriptional repression. Of the eleven PRMTs, PRMT5 is closely associated with
transcriptional repression (Pal and Sif, 2007; Pal et al., 2004); its repressive function is
attributed to symmetric di-methylation of histone 4 (arginine 3) and histone 3 (arginine 8)
(Krause et al., 2007).

These histone modifications were recently linked with the

subsequent recruitment of DNMT3, linking histone methylation with DNA methylation
(Zhao et al., 2009).
Regulation of PRMT5 function remains poorly understood and modification of
PRMT5 by phosphorylation, acetylation or ubiquitylation has not been reported. In
contrast, association of PRMT5 with MEP50 is an activating event (Krause et al., 2007).
In addition, association of COPR5 with PRMT5 changes the balance of activity from
H3R8 towards H4R3 (Lacroix et al., 2008). While PRMT5 is not detectably modified in a
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CDK4-dependent manner, a multiplicity of approaches revealed MEP50 to be a direct
substrate. The data provided demonstrate that phosphorylation of T5, and perhaps S264,
of MEP50 contributes to increased PRMT5/MEP50 methyltransferase activity in cells
harboring nuclear cyclin D1/CDK4. As addition of purified MEP50 to recombinant
PRMT5 is sufficient to activate PRMT5 methyltransferase function (Krause et al., 2007),
the most direct model is that cyclin D1-dependent phosphorylation functions as a switch
to facilitate MEP50-dependent, structural alterations in PRMT5 that contribute to
enhanced catalysis or perhaps increased affinity for substrates which translates into more
efficient methylation.

Transcriptional regulation of CUL4A/B by cyclin D1
Previous work demonstrated that nuclear, active cyclin D1/CDK4 during S-phase
leads to reduced CUL4A/B expression (Aggarwal et al., 2007). While the underlying
mechanism remained elusive, a large body of work associating cyclin D1 with
transcriptional regulation suggested that regulation could be direct. For example, cyclin
D1 was first noted to associate with the estrogen receptor (ER) to coordinate ligandindependent expression of ER targets independent of CDK activation (Lamb et al., 2000;
McMahon et al., 1999; Zwijsen et al., 1998; Zwijsen et al., 1997). Subsequently, cyclin
D1 was shown to bind and regulate the activities of androgen receptor (Knudsen et al.,
1999), DMP1 (Hirai and Sherr, 1996), and C/EBPb (Lamb et al., 2003). Our current
work demonstrates that regulation reflects CDK4-dependent phosphorylation of MEP50,
which in turn increases PRMT5-dependent histone methylation of target genes, reducing
their expression. While previous work supports a model where cyclin D1 functions as a
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molecular bridge between DNA-bound transcription factors and co-activators/repressors,
our data reveal not only that cyclin D1 occupies promoter regions of a target gene, but
also that regulation reflects CDK-dependent phosphorylation of a recruited epigenetic
regulatory enzyme.

Consistently, recent work utilizing genome-wide ChIP analysis

demonstrated that cyclin D1 is enriched in regions near the transcriptional start site of a
large number of genes (Bienvenu et al., 2010), providing additional evidence for cyclin
D1 directly regulating gene expression. It is intriguing to note that the strongest H4R3
methylation occurs near the predicted transcription start site of both CUL4A and CUL4B.
The role of CDK4, while perhaps unexpected in the context of transcription, is not
totally unexpected in the context of tumorigenesis given that CDK activation is central to
the function of cyclin D1 during neoplastic transformation. That MEP50 is a substrate for
cyclin D1/CDK4 makes the PRMT5/MEP50 complex one of a limited number of cyclin
D1-dependent substrates. Previously, only the RB family members (Kato et al., 1993) and
Smad3, a key mediator for TGF- anti-proliferative responses (Liu and Matsuura, 2005;
Matsuura et al., 2004), have been established as substrates in vitro and in vivo.
While increased cyclin D1T286A/CDK4-dependent PRMT5/MEP50 function is
required for CUL4 loss and CDT1 overexpression, we cannot rule out the contribution of
additional mechanisms that contribute to CUL4 regulation. For example, neither cyclin
D1 nor PRMT5/MEP50 has intrinsic DNA binding properties. Thus, it remains unclear
how cyclin D1T286A/CDK4 promotes the targeting to this locus. In addition, we
questioned the possibility that cyclin D1T286A might result in the recruitment of histone
deacetylases and thereby impact CUL4 expression. Our results indicated that HDAC

106

inhibition resulted in increased CUL4 expression regardless of cyclin D1T286A/CDK4
suggesting a non-specific effect (data not shown).

Signaling through PRMT5/MEP50 is not limited to lymphoid tumors harboring
mutant cyclin D1 alleles.
Cyclin D1T286A/CDK4 increases PRMT5 methyltransferase activity in vivo
through MEP50, revealing a pathway where PRMT5 facilitates cyclin D1T286A/CDK4
dependent re-replication and survival of murine tumors harboring a lymphoid-specific
D1T286A transgene. However, it is important to note that this mechanism is not
restricted to this model system or this particular cyclin D1 allele for the following
reasons. First, knockdown of Fbx4, the specificity component of the cyclin D1 E3 ligase,
stabilizes nuclear cyclin D1/CDK4 complexes in the nucleus during S-phase and thereby
increases PRMT5-dependent histone methylation resulting in CUL4 loss. Second, human
tumors harboring inactivating mutations in Fbx4 and subsequent nuclear accumulation of
endogenous cyclin D1-dependent kinase, exhibit a dramatic increase in H4R3
methylation. Finally, cyclin D1/CDK4-MEP50/PRMT5 complexes are observed in
esophageal carcinoma cell lines harboring cyclin D1P287A. These independent findings
implicate aberrant nuclear cyclin D1 in transcriptional repression of CUL4.
Collectively, our current work supports a model wherein accumulation of nuclear
cyclin D1/CDK4 during S-phase triggers increased PRMT5/MEP50 activity, thereby
specifically reducing CUL4 expression (and triggering downstream stabilization of CUL4
ligase targets such as CDT1, Figure 4.9). Our functional analysis revealed that PRMT5 is
necessary for cyclin D1-mediated cell transformation and further that tumors harboring
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deregulated cyclin D1 exhibit increased PRMT5-dependent histone methylation. Future
efforts to determine the global gene expression pattern altered through cyclin D1dependent regulation of PRMT5 and which of these specifically contribute to neoplastic
growth will be of significant importance.
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CHAPTER V:
DISCUSSION, CONCLUSIONS, AND FUTURE DIRECTIONS

The section entitled
“Cyclin D1 regulation following the G1/S transition and genotoxic stress” and
“Checkpoint signaling directs cyclin D1 degradation”
have been published in part (including Figure 5.1) in:

Pontano L.L. and Diehl J.A. (2009).
DNA damage-dependent cyclin D1 proteolysis:
GSK3 holds the smoking gun. Cell Cycle 8 (6): 824-827.
(Pontano and Diehl, 2009)
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Temporal CDK regulation is achieved through alternating phases of cyclin
expression, followed by cyclin destruction via ubiquitin-mediated proteolysis. Disruption
in this balance promotes aberrant CDK activity, thereby creating a cellular environment
conducive to neoplastic transformation. This concept has been well illustrated by cyclin
D1/CDK4; alterations in cyclin D1 phosphorylation, nuclear export, and Fbx4-mediated
degradation facilitate accumulation of active cyclin D1/CDK4 kinase in the nucleus
following the G1/S transition, driving DNA re-replication and genomic instability. While
previous work defined these molecular events, mechanistic details of nuclear cyclin
D1/CDK4-dependent genomic instability remained elusive. The work presented in this
thesis described a role for SCFFbx4 in regulating cyclin D1 following genotoxic stress, and
genetic analysis revealed that Fbx4 functions as a haploinsufficient tumor suppressor in
vivo by controlling cyclin D1 accumulation. Critically, this work elucidated a novel
mechanism wherein nuclear cyclin D1/CDK4 kinase elicits oncogenic effects by
modulating epigenetic regulation. This chapter provides a broad perspective of how
deregulated cyclin D1/CDK4 drives cell cycle progression and genomic instability
necessary for tumor initiation, highlighting the impact of aberrant cyclin D1/CDK4
activity on checkpoint responses and gene expression. Finally, I will discuss how these
mechanistic studies may influence potential therapeutic strategies for cyclin D1overexpressing tumors.

Cyclin D1 regulation following the G1/S transition and genotoxic stress.
Ubiquitin-mediated cyclin D1 proteolysis following the G1/S transition counters
its mitogen-dependent accumulation during G1 phase. Previous work established that
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cyclin D1 accumulation is antagonized by GSK3-dependent T286 phosphorylation,
triggering nuclear export, and SCFFbx4-mediated ubiquitylation within the cytoplasm,
targeting cyclin D1 for proteasomal degradation (Alt et al., 2000; Diehl et al., 1998; Diehl
et al., 1997; Lin et al., 2006). Although the cellular machinery responsible for this
process was previously identified, how this regulatory pathway interfaces to cellular
stress responses remained to be established. Here, I identified a phosphorylation- and
Fbx4-dependent cyclin D1 degradation mechanism in response to genotoxic stress.
Following DSB induction, cyclin D1 is rapidly phosphorylated by GSK3, facilitating
nuclear export and subsequent recognition by Fbx4. Critically, nuclear cyclin D1/CDK4
retention following DNA damage compromises the intra-S-checkpoint response, resulting
in chromosomal instability.
Previous work suggested that phosphorylation may be superfluous for DNA
damage mediated cyclin D1 proteolysis, as phosphorylation-independent cyclin D1
degradation mediated by APC/C was shown to elicit G1 arrest (Agami and Bernards,
2000). Consistent with this notion, cyclin D1 is not phosphorylated in G1 phase
following genotoxic stress; however, rapid cyclin D1 turnover was not observed at this
time (unpublished data not shown). Furthermore, phosphorylation-refractory cyclin
D1T286A is not degraded in response to DNA damage. Several kinases have been
implicated in cyclin D1 T286 phosphorylation during normal cell cycle progression and
various stress conditions, including IB kinase alpha (IKK) and p38SAPK (Casanovas et
al., 2000; Kwak et al., 2005). While manipulation of these kinases did not impact DNA
damage-dependent cyclin D1 phosphorylation, our work revealed that GSK3 activity
increases in response to genotoxic stress, and inhibition of GSK3 via shRNA, small
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molecule inhibitors or dominant negative alleles all effectively inhibit cyclin D1
phosphorylation, highlighting the significance of this kinase for proper control of cyclin
D1 accumulation.
The prerequisite for cyclin D1 phosphorylation in DNA damage-driven
degradation suggested a role for the SCFFbx4 ligase in this process. Consistent with this
notion, shRNA-mediated knockdown of both Fbx4 and B crystallin attenuated cyclin
D1 degradation; of significance, cyclin D1 regulation could be restored in B crystallindeficient cell lines following introduction of ectopic B crystallin, suggesting that this
SCFFbx4 co-factor is essential for cyclin D1 recognition. A question that arises, then, is
whether other G1/S cyclins are also subject to accelerated degradation. Cyclin D2 and
cyclin E, for instance, are phosphorylated by GSK3, but are not regulated by Fbx4.
Importantly, cyclin D2 and cyclin E accumulation is unaffected by DNA damage,
highlighting the specific nature of cyclin D1 regulation in the DNA damage response.
My work supports a model where genotoxic stress-mediated cyclin D1
degradation occurs in an Fbx4-dependent manner at the G1/S transition, in contrast to
phosphorylation-independent degradation via APC/C (Agami and Bernards, 2000) and
recent work suggesting Fbxo31-mediated degradation during G1 (Santra et al., 2009).
What accounts for these differences? Work describing APC/C-dependent cyclin D1
regulation was performed in MCF-7 cells, a cell line deficient for B crystallin and thus,
SCFFbx4 ligase function toward cyclin D1 (Lin et al., 2006), implying that these cells use
alternative degradation pathways to terminate cyclin D1 protein expression. Consistent
with this notion, phosphorylation-deficient cyclin D1 proteins are degraded, albeit with
dramatically extended kinetics. Furthermore, GSK3 is inactive in G1 and cannot
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facilitate Fbx4 ligase activation or cyclin D1 phosphorylation. The Fbxo31 model
suggests that direct, ATM-dependent phosphorylation facilitates Fbxo31 stabilization,
permitting recognition of ERK-phosphorylated cyclin D1 by this SCF ligase in G1-phase
melanoma cells. Again, it is possible that these cells have adopted alternative signaling
solutions for regulating cyclin D1, as our work using fibroblasts and various epithelial
cell lines indicate that cyclin D1 is not phosphorylated following G1-phase DNA
damage. Furthermore, Fbxo31 knockdown in fibroblasts does not influence genotoxic
stress-mediated cyclin D1 destruction (unpublished data not shown). While these
alternative models predict that G1-phase cyclin D1 degradation is important for cell cycle
arrest prior to S-phase, our current model suggests that perhaps a more critical time to
ensure cyclin D1 destruction is following the G1/S transition, as nuclear retention of
cyclin D1/CDK4 kinase perturbs S-phase fidelity and DNA damage checkpoint integrity.

Checkpoint signaling orchestrates cyclin D1 degradation.
Rapid GSK3- and Fbx4-dependent cyclin D1 destruction suggests that the
canonical cyclin D1 proteolysis pathway is activated by DNA damage signaling effectors.
Replication stress associated-ATR activation has been proposed to regulate cyclin D1
phosphorylation and degradation during S-phase (Hitomi et al., 2008). In contrast, we
found that DSB-inducing treatments including HU, IR, and camptothecin (CPT) induced
rapid cyclin D1 phosphorylation and degradation downstream of ATM activation,
whereas activation of ATR via aphidicolin treatment was not sufficient to trigger cyclin
D1 loss. Furthermore, ATM inhibition or ablation abrogates cyclin D1 phosphorylation
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following genotoxic stress; however, ATR deletion or shRNA-mediated knockdown does
not influence cyclin D1 regulation.
Although ATM signaling is required for GSK3-dependent cyclin D1
phosphorylation following genotoxic stress, the precise molecular underpinnings that
connect ATM, GSK3, and cyclin D1 remain to be established. Several different models
of ATM-dependent cyclin D1 phosphorylation can be considered. First, activation of
ATM and its downstream effectors, such as Chk2, could directly activate GSK3 (Lee et
al., 2007). Consistent with this notion, an increase in GSK3 kinase activity following
DNA damage was noted. Second, ATM-dependent regulation of GSK3 interacting
proteins could bring the kinase in proximity to cyclin D1 in the nucleus, increasing the
efficiency of phosphorylation. Finally, ATM-dependent modification of a cyclin D1interacting protein could induce a conformational change, making cyclin D1 a better
GSK3 substrate. Our initial work to parse out this ATM-dependent signaling pathway
reveal that Chk2 only modestly stabilizes cyclin D1 at early time points following DNA
damage, suggesting that ATM itself or alternative downstream effector(s) regulate this
DNA damage response. Consequently, further characterizing the connection between
ATM and cyclin D1 regulation is an exciting question and a future area for investigation.
Considering the above models for increased GSK3 activity, the question arises
whether SCFFbx4 ligase activity is also regulated by DNA damage. GSK3 catalyzes both
nuclear cyclin D1 phosphorylation, promoting nuclear export, and cytoplasmic Fbx4
phosphorylation, triggering its dimerization and activation (Barbash et al., 2008; Diehl et
al., 1998). Are these events linked following DNA damage? Our data suggest that cyclin
D1 phosphorylation is the critical event for degradation, as phosphorylation-deficient
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mutants never reach the cytoplasm. However, the possibility of both increased cyclin D1
phosphorylation and increased Fbx4-dependent ligase activity contributing to rapid
kinetics of cyclin D1 loss was quite intriguing. Work presented in chapter 3 began to
address this question, as I demonstrated that GSK3-dependent Fbx4 phosphorylation
increases following S-phase DNA damage. Moreover, my work revealed that enhanced
phosphorylation correlates with a marked increase in SCFFbx4 ubiquitin ligase activity
following S-phase DNA damage. While these data indicate that both cyclin D1 and Fbx4
are targeted by GSK3, the distinct mechanisms that control both nuclear/cytoplasmic
activation and localization of this kinase remain to be established.
Cyclin D1 proteolysis downstream of ATM activation is a cellular checkpoint
response to maintain genome integrity, supporting a model wherein DSB-dependent
ATM activation triggers rapid, Fbx4-dependent cyclin D1 degradation (Figure 5.1A). In
contrast, expression of phosphorylation-deficient cyclin D1 or inactivation of Fbx4
promotes an RDS phenotype associated with CDT1 stabilization and maintenance of
MCM proteins on chromatin. Sustained replication in the face of DNA damage
potentiates genomic instability. While genomic instability can drive genetic alterations
that provide a growth advantage to proliferating cells, severe DNA damage invokes cell
death through apoptosis or mitotic failure. Significantly, our recent work demonstrated
that nuclear accumulation of cyclin D1 sensitizes cells to the DNA damaging, S-phasespecific chemotherapeutic agent CPT. Ultimately, these findings imply that loss of Fbx4
control compromises the cellular checkpoint response to DNA-damaging chemotherapy,
thereby driving substantial genomic instability and cell death (Figure 5.1B).
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Fbx4 is a bona fide tumor suppressor.
Identification of Fbx4 and B crystallin as key cyclin D1 regulatory components
ultimately suggested that these proteins could function as potential tumor suppressors.
Indeed, this notion was first validated when a screen of human tumors revealed
downregulation of Fbx4 and B crystallin at the protein and mRNA levels (Lin et al.,
2006). Additionally, the B crystallin gene is located on chromosome 11q22.3-q23.1, a
region commonly deleted in cancer (Dohner et al., 1999). Subsequent analyses revealed
that Fbx4 is frequently mutated in esophageal carcinoma, with a majority of mutations
disrupting residues necessary for ligase dimerization/activation (Barbash et al., 2008).
Such sequencing efforts support a role for Fbx4 in tumor suppression, and future analysis
of many different tumor subsets harboring cyclin D1 protein overexpression will likely
reveal additional alterations. For example, a prime suspect for Fbx4 mutation or
inactivation is mantle cell lymphoma (MCL). A genetic hallmark in MCL is the t(11;14)
chromosomal translocation, resulting in ectopic cyclin D1 expression (Marzec et al.,
2006). While overexpression of wild type cyclin D1 is typically insufficient for
neoplastic transformation, mutation or loss of Fbx4 could facilitate nuclear cyclin D1
accumulation necessary for this process. Furthermore, a subset of 11q22-23 deletions in
MCL affect ATM expression; loss of ATM could, in turn, prevent cyclin D1 degradation
in response to DNA damage during the transformation process, thereby providing a
“second hit” through mechanisms described in chapter 2 of this thesis.
In addition to tumor sequencing studies, cell culture and orthotopic transplant
models suggested that Fbx4 attenuation or inactivation permits cell transformation.
Knockdown of Fbx4 promotes anchorage-independent growth; critically, Fbx4
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knockdown in cyclin D1-/- MEFs fails to recapitulate this phenotype, suggesting that
transformation depends on cyclin D1 stabilization. Furthermore, inhibition of Fbx4
function cooperates with cyclin D1 in driving tumor growth, as MMTV-D1 transgenic
mammary epithelial cells infected with F-box Fbx4 (dominant negative) readily formed
tumors in fat pads of NOD/SCID mice (Barbash et al., 2008). Finally, Fbx4 attenuation
facilitates nuclear cyclin D1 accumulation and chromosomal instability following
genotoxic stress. While these findings indirectly implicate Fbx4 as a tumor suppressor,
experiments that directly address this question have not been documented to date.
Consequently, in chapter 3 of thesis, Fbx4-dependent tumor suppression was directly
interrogated through targeted disruption of the murine Fbx4 locus. These data reveal that
Fbx4 loss does not impact development; however, a significant percentage of Fbx4+/- and
Fbx4-/- mice succumb to age-associated malignancy.
The most common tumor phenotype in Fbx4+/- and Fbx4-/- aged mice are large cell
lymphomas of B- and T-cell origin initiating in the spleen and mesenteric node;
lymphoma infiltrates were also observed in the liver and intestine. Less frequent
malignancies including histiocytic sarcoma/dendritic cell tumors, hemangioma, early
myeloid tumors, and mammary, uterine, and hepatocellular carcinomas were observed
(Table 2). While tumors of epithelial cell origin are expected based on the requirement
for cyclin D1 in proliferation of these tissues, the frequent occurrence of lymphoid
tumors is quite intriguing, since a large body of evidence suggested that cyclin D2/D3
drives proliferation of the lymphocyte compartment, while cyclin D1 protein is not
expressed at significant levels. It was initially thought that control of cyclin D1
expression in lymphocytes occurred at the transcriptional level; however, our data
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revealing cyclin D1 accumulation in Fbx4-deficient normal lymphoid tissue and tumors
support a requisite role for posttranslational degradation in limiting cyclin D1
accumulation. Additionally, frequent incidence of extramedullary hematopoiesis and
early myeloid malignancy suggests bone marrow failure; assessing the role of Fbx4 in
hematopoietic development and bone marrow homeostasis is an area for future work.
Fbx4+/- lymphomas retain Fbx4 expression, consistent with human cancer data
revealing hemizygous Fbx4 mutations (Barbash et al., 2008), suggesting that Fbx4
functions as a haploinsufficient tumor suppressor in vivo. Furthermore, Fbx4+/- and Fbx4-/MEFs are susceptible to single step, Ras-mediated transformation, also supporting
haploinsufficiency in vitro. Another well-studied F-box protein, Fbw7, was initially
thought to be a haploinsufficient tumor suppressor based on frequent hemizygous
mutations in cancer and rare incidence of loss or deletion; however, biochemical
characterization of such mutations within the substrate binding domain revealed
dominant-negative character toward the remaining wild type protein, and Fbw7+/- mice
are refractory to spontaneous tumorigenesis (Onoyama et al., 2007; Tetzlaff et al., 2004;
Welcker and Clurman, 2008). In contrast to Fbw7, our work demonstrates that expression
of a single Fbx4 allele is not sufficient to maintain cell homeostasis.
While pre-malignant or normal Fbx4+/- and Fbx4-/- tissues including the lung
exhibit cyclin D1 protein accumulation, lung adenocarcinomas and other epitheliallineage tumors are not frequently observed. It is possible that conventional Fbx4 ablation
allows developmental re-wiring of cyclin D1 regulatory circuits in these tissues, resulting
in compensatory pathways for cyclin D1/CDK4 regulation. This concept is also
illustrated in MEFs. Cyclin D1 stability increases from 15 minutes in primary wild type
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MEFs to approximately 35 minutes in Fbx4-/- MEFs. Although Fbx4 loss permits cyclin
D1 stabilization and nuclear accumulation, cyclin D1 is still relatively unstable compared
to constitutively nuclear cyclin D1T286A. Furthermore, the protracted tumor latency in
Fbx4+/- and Fbx4-/- mice suggests that alternative mechanisms may initially repress
neoplastic effects of cyclin D1/CDK4 or a second hit, such as p53 inactivation, may be
required for neoplastic transformation. Therefore, development of a conditional Fbx4
allele is required for tissue-specific Fbx4 ablation in the adult mouse; this genetic
manipulation will mirror the somatic inactivating mutations observed in human cancers.
Additionally, crossing conventional Fbx4-/- mice onto a p53 heterozygous background
could potentially address whether p53 inactivation is required for tumorigenesis; one
would suspect that p53 LOH would accelerate tumor onset in conventional Fbx4-/- mice.
Similarly, crossing Fbx4-/- mice with an oncogenic driver such as K-Ras (G12D) could
answer the question as to whether loss of Fbx4 accelerates tumor progression.
In addition to tumor analysis, molecular characterization of Fbx4+/- and Fbx4-/MEFs revealed significant nuclear cyclin D1 accumulation, with concomitant DNA
damage checkpoint activation, as evidenced by the presence of H2AX foci and p53
accumulation. Fbx4+/- and Fbx4-/- MEFs exhibit similar onset of senescence, and culture
under physiological oxygen conditions did not alleviate the DNA damage phenotype,
suggesting that an alternative, cell intrinsic mechanism underlies the DNA damage. In
addition, DNA damage is not likely to result from stabilization of the other known Fbx4
substrate, Trf1, given that telomere uncapping effects of Trf1 stabilization would take
many generations due to the extremely long telomeres observed in laboratory mouse lines
(Lee et al., 2006). Consistent with this notion, nuclear cyclin D1 accumulation correlated
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with CDT1 stabilization in S-phase MEFs, suggesting that DNA re-replication promotes
DNA damage and subsequent chromosomal instability when cells are challenged with
extrinsic DNA damaging agents. Taken together, our data support a model wherein cyclin
D1 nuclear accumulation in the absence of Fbx4 promotes CDT1 stabilization, DNA rereplication, and genomic instability, thereby charging the cell for potential
transformation. p53 induction in response to DNA damage initially limits proliferation;
however, subsequent alterations in the p53 pathway then facilitate neoplastic growth and
tumor formation (Figure 5.2).
The studies presented in chapter 3 support the notion that Fbx4 expression is
essential for homeostasis in somatic cells. However, several questions regarding Fbx4
regulation and function remain to be answered. For example, it is unclear whether
accumulation of novel Fbx4 substrates contributes to neoplastic transformation in concert
with cyclin D1. To address this in a timely manner, Fbx4-/-; cyclin D1-/- MEFs should be
generated and utilized in cell transformation assays with constitutively active Ras in
vitro. Furthermore, the Fbx4 crystal structure in complex with its other known substrate,
Trf1 was recently solved, revealing that the hydrophobic interface between Fbx4 and
Trf1 is necessary for substrate-Fbx4 association (Li and Hao, 2010; Zeng et al., 2010). It
is of interest to determine whether critical residues within this region are altered in
cancer, thereby precluding cyclin D1 binding. Interestingly, the Fbx4 structure revealed
that its C-terminal substrate-binding region consists of an atypical small GTPase domain.
While this domain lacks nucleotide-binding capacity, it likely functions as scaffold for
protein interactions. This region may be important for B crystallin binding and
subsequent cyclin D1 recognition. In contrast, Trf1 recognition occurs in a
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phosphorylation- and B crystallin-independent manner. Elucidation of these different
mechanisms for substrate recognition is required to fully understand the molecular
architecture and function of SCFFbx4. Additionally, F-box independent functions of Fbx4,
such as serving as a scaffold for protein-protein interactions through its GTPase-like
domain, remain to be established.

Additional cyclin D1 ubiquitin ligases?
As mentioned previously, both APC/C and SCFFbxo31 have been implicated in
cyclin D1 regulation following genotoxic stress. The work presented in chapter 2
suggests that the APC/C does not play a major role in cyclin D1 regulation following G1
or S-phase DNA damage in fibroblasts and several epithelial cell lines, since cyclin D1
levels are unaltered in G1 phase and phosphorylation-dependent degradation mediated by
Fbx4 regulates cyclin D1 accumulation following the G1/S transition. Interestingly,
recent work revealed that C/EBP induces expression of the APC/C component CDC27,
leading to degradation of cyclin D1, along with well established APC/C targets Skp2 and
cyclin B (Pawar et al., 2010). In agreement with previous work describing APC/C
mediated cyclin D1 degradation, this group utilized MCF-7 cells lacking B crystallin,
and CDC27-APC/C mediated cyclin D1 ubiquitylation remains to be demonstrated in
vitro. It is possible that APC/C activity may serve as an additional mechanism to limit
cyclin D1 accumulation in G1 phase when GSK3 is inactive; however, precise signaling
events that potentially facilitate specific recognition by CDC27 or APC/C itself are
unclear.
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Additional evidence suggested that CUL7/Fbw8 or SCFFbw8 complexes regulate
polyubiquitylation of ERK-phosphorylated cyclin D1 at the G1/S transition (Okabe et al.,
2006). However, loss of Fbw8 or CUL7 in vivo results in reduced body size and severe
proliferative defects in MEFs (Tsutsumi et al., 2008). These results are inconsistent with
the expected phenotype of cyclin D1 accumulation, given that overexpression of cyclin
D1 facilitates cell growth. ERK-mediated cyclin D1 phosphorylation is also proposed to
facilitate Fbxo31-dependent cyclin D1 ubiquitylation in G1 phase. Importantly, in vivo
evidence for direct ERK-mediated T286 phosphorylation is weak, and ERK has not been
convincingly demonstrated as a cyclin D1 T286 kinase in vitro. Furthermore, Fbxo31 is
an

inherently

unstable

protein

that

is

stabilized

following

ATM-dependent

phosphorylation; Fbxo31 stabilization is thought to allow its association with cyclin D1
in response to G1 phase genotoxic stress (Santra et al., 2009). Contrary to these findings,
knockdown of Fbxo31 does not affect DNA damage-dependent cyclin D1 degradation,
and cyclin D1 is not phosphorylated in G1 phase fibroblasts or epithelial cell lines (data
not shown). These results suggest that the ATM-Fbxo31-cyclin D1 axis may be specific
to the particular melanoma cell line utilized in that study.
Correlative evidence linking Fbx4 or B crystallin loss or inactivation in tumorderived cells with cyclin D1 overexpression suggests that SCFFbx4 function keeps cyclin
D1 in check. Consistently, studies directly testing this hypothesis using Fbx4- or B
crystallin-specific shRNAs or genetic Fbx4 ablation also reveal significant cyclin D1
accumulation. Although these data support a requisite role for Fbx4 in regulating cyclin
D1 accumulation, it is important to note that cyclin D1 is still degraded, despite
dramatically reduced kinetics, suggesting that additional ligases may play a secondary
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role in limiting cyclin D1 protein levels. Nevertheless, Fbx4 ablation or shRNA-mediated
knockdown is sufficient to elicit cyclin D1 nuclear accumulation, unmasking cyclin D1’s
oncogenic potential. The Fbx4-cyclin D1 axis, therefore, is a classic tumor suppressoroncogene relationship that must remain balanced in cycling cells.

Mechanism of nuclear cyclin D1-driven genomic instability.
Cyclin D1 is subject to strict posttranslational regulation to ensure its timely
destruction at the G1/S transition. Phosphorylation-dependent nuclear export and Fbx4dependent ubiquitylation/degradation during S-phase constrain nuclear cyclin D1/CDK4
kinase activity (Alt et al., 2000; Benzeno et al., 2006; Lin et al., 2006). This regulation is
essential since aberrant nuclear cyclin D1/CDK4 activity during S-phase promotes DNA
re-replication (Aggarwal et al., 2007), transformation in vitro (Alt et al., 2000), and
tumorigenesis in vivo (Gladden et al., 2006; Lin et al., 2008). Initial molecular dissection
of this process in Eμ-D1T286A-driven lymphomas and cell culture models revealed
downregulation of CUL4 expression in a cyclin D1/CDK4-dependent manner; CUL4
loss facilitates CDT1 stabilization, triggering DNA re-replication, genomic instability and
acquisition of fortuitous mutations necessary for tumor initiation (Aggarwal et al., 2007).
This previous work highlighted dependence upon CDK4 activity, suggesting that
cyclin D1/CDK4 may phosphorylate novel nuclear substrates during S-phase, leading to
transcriptional repression at key target loci. The collaborative work presented in chapter 4
identified a critical regulatory pathway wherein nuclear cyclin D1/CDK4 kinase elicits
neoplastic effects through modulation of the PRMT5/MEP50 methyltransferase; MEP50
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phosphorylation on T5 mediates PRMT5-dependent histone methylation and subsequent
transcriptional repression, providing a novel mechanism for cyclin D1/CDK4-driven cell
transformation. Importantly, inhibition of PRMT5/MEP50 activity via siRNA, arginine
methyltransferase inhibitors, or overexpression of non-phosphorylatable MEP50 T5A or
kinase-defective CDK4 (K35M) restores CUL4 expression and CDT1 degradation,
consistent with a model where PRMT5/MEP50 represents a key molecular target of
nuclear cyclin D1/CDK4 during S-phase (Figure 4.9).
Identification of a PRMT5-cyclin D1 relationship was especially intriguing,
considering that PRMT5 catalyzes arginine methylation on a variety of substrates,
including myelin basic protein (Ghosh et al., 1988), SM proteins (Friesen et al., 2001),
p53 (Jansson et al., 2008), and most importantly, histone H3 and H4. Furthermore, there
are 11 different PRMTs expressed in mammalian cells, yet only PRMT5 is associated
with transcriptional repression (Pal and Sif, 2007; Pal et al., 2004). Additionally, H4R3
and H3R8 methylation marks were recently linked with the recruitment of DNMT3 to
DNA, suggesting that coordinated histone methylation with DNA methylation mediates
transcriptional repression (Zhao et al., 2009).
Implication of cyclin D1 in transcriptional regulation is not a new concept, as
various studies suggested that cyclin D1 directly associates with transcription factors and
transcriptional regulatory complexes. For instance, early work suggested that cyclin D1
association with estrogen receptor (ER) coordinates ligand-independent induction of ER
targets (Lamb et al., 2000; McMahon et al., 1999; Zwijsen et al., 1998; Zwijsen et al.,
1997). Subsequent work also supported a role for cyclin D1 in regulating androgen
receptor activity (Knudsen et al., 1999), DMP1 (Hirai and Sherr, 1996), and C/EBP
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(Lamb et al., 2003). Therefore, a model for cyclin D1 in transcriptional regulation was
that cyclin D1 functions as a molecular bridge between transcription factors and coactivator or repressor complexes. However, all of these studies suggested that cyclin D1
elicits transcriptional effects independent of CDK4 activation.
Critically, the results presented in chapter 4 indicate that cyclin D1 modulates
PRMT5 activity through CDK4-dependent phosphorylation of the activating co-factor
MEP50, challenging the previous model of cyclin D1-dependent, CDK4 independent
transcriptional regulation. This is the first documented example of cyclin D1/CDK4dependent phosphorylation of an epigenetic regulatory enzyme, demonstrated both in
vivo and in vitro. The exact mechanism underlying methyltransferase activation upon
MEP50 phosphorylation is yet to be defined; however, the most direct model is that
CDK4-dependent phosphorylation functions as a switch to facilitate MEP50-dependent
structural alterations in PRMT5 that contribute to enhanced catalysis or increased affinity
for substrates, leading to more efficient substrate methylation. Furthermore, cyclin
D1/CDK4 and PRMT5/MEP50 occupy the promoter regions of CUL4A and CUL4B;
whether cyclin D1/CDK4 is directly associated with DNA or binding through
PRMT5/MEP50 or other chromatin modifying enzymes remains to be established.
Consistent with our findings, recent work utilizing genome-wide ChIP revealed that
cyclin D1 is enriched in regions near transcriptional start sites of many genes, providing
additional evidence for cyclin D1 directly regulating gene expression (Bienvenu et al.).
While it is clear that cyclin D1/CDK4 and PRMT5/MEP50 occupy the CUL4
promoters, future work is required to define the precise mode of cyclin D1/CDK4
recruitment to chromatin. Cyclin D1 and PRMT5/MEP50 lack defined intrinsic DNA
134

binding properties, suggesting that association with additional DNA binding proteins is
important for recruitment. Furthermore, the cyclin D1/CDK4/PRMT5/MEP50 ternary
complex is likely associated with large chromatin remodeling complexes, since the
SWI/SNF component Brg1 is present in cyclin D1/CDK4-containing PRMT5/MEP50
complexes. Recent evidence suggests that the Kruppel-like associated box-zinc finger
protein ZNF224 interacts with PRMT5, facilitating PRMT5 recruitment to the L-type
aldolase A promoter and subsequent transcriptional repression (Cesaro et al., 2009).
Identification of additional PRMT5/MEP50/cyclin D1/CDK4 complex components, such
as DNA binding zinc-finger proteins, will assist in elucidating how this ternary complex
is assembled and recruited to chromatin.
CDK4-dependent transcriptional regulation is a novel concept; however, this is
not unexpected in the context of tumorigenesis given that CDK activation is central to the
function of cyclin D1 during cell transformation. Furthermore, identification of MEP50
as a novel cyclin D1/CDK4 target is of interest, given the small repertoire of previously
characterized CDK4 substrates, including the Rb family members (Kato et al., 1993; Liu
and Matsuura, 2005; Matsuura et al., 2004). Establishment of MEP50 as a CDK4
substrate that contributes to epigenetic regulation of target genes associated with cancer
establishes a paradigm whereby cyclin D1 regulation of gene expression occurs
independently of Rb yet remains kinase dependent. This raises the question of whether
cyclin D2/D3/CDK4 and cyclin E/CDK2 complexes are capable of phosphorylating
MEP50. Little is known with regard to tumorigenic activity of constitutively nuclear
cyclin D2 and D3, and cyclin E is typically nuclear at the G1/S transition, making a
regulatory relationship between these molecules and PRMT5 unlikely. A more attractive
135

model is one wherein exclusive sequences within cyclin D1 or association of a novel
bridging adapter protein facilitate specific cyclin D1/CDK4-PRMT5/MEP50 ternary
complex assembly and subsequent regulation.
Collectively, the work presented in chapter 4 supports a model wherein
accumulation of active, nuclear cyclin D1/CDK4 during S-phase triggers increased
PRMT5/MEP50 activity, thereby specifically reducing CUL4 expression (and triggering
downstream stabilization of CUL4 ligase targets such as CDT1). Functional analysis
revealed that PRMT5 is necessary for cyclin D1-mediated DNA re-replication and cell
transformation, and tumors harboring deregulated cyclin D1 exhibit increased PRMT5dependent histone methylation. Critically, inhibition of arginine methyltransferase
activity in cyclin D1T286A expressing transformed splenocytes impairs survival of these
tumor cells in vitro, making PRMT5 an attractive target for therapeutic development.
Finally, future efforts to determine the global gene expression pattern altered through
cyclin D1-dependent regulation of PRMT5 and which genes specifically contribute to
neoplastic growth will be of significant importance.

Loss of checkpoint integrity and nuclear cyclin D1-driven tumorigenesis.
A current model for cyclin D1-mediated genomic instability and neoplastic
transformation is as follows: nuclear cyclin D1/CDK4 accumulation in S-phase activates
the PRMT5 methyltransferase through MEP50 phosphorylation. PRMT5/ MEP50 then
methylates H3 and H4 at key target promoters, including CUL4A and CUL4B, triggering
transcriptional repression. Loss of CUL4 promotes CDT1 stabilization, facilitating DNA
re-replication and subsequent genomic instability (Figure 5.3A). DNA damage (DSBs)
136

accrued due to re-replication/replication fork collision activates the ATM-dependent
checkpoint response, leading to cell cycle arrest, DNA repair, or p53-dependent apoptosis
if damage is irreparable; this checkpoint function is critical to suppress nuclear cyclin
D1-driven transformation. For example, pre-malignant spleens expressing the EμD1T286A transgene exhibit markers of DNA damage checkpoint activation such as
phosphorylated ATM, Chk2 and H2AX, with a concomitant induction of apoptosis
(Aggarwal et al., 2007). Sustained checkpoint activation provides a selective pressure for
p53 mutation or inactivation, and alterations in the p53 pathway are commonly observed
in cyclin D1T286A-driven lymphomas (Figure 5.3B), (Aggarwal et al., 2007; Gladden et
al., 2006). Furthermore, p53 heterozygosity substantially accelerates cyclin D1T286Adriven tumor formation, suggesting that intact checkpoint function is essential to prevent
neoplastic growth (Aggarwal et al., 2007).
These findings led to the question of whether loss of the DSB checkpoint
responder ATM in the presence of nuclear cyclin D1T286A would sensitize cells to
chromosomal instability, resulting in translocation events that facilitate cell
transformation and tumor outgrowth (Figure 5.3C). My preliminary work suggests that
loss of ATM may, in fact, accelerate cyclin D1T286A-driven lymphomagenesis in a
mouse model. Furthermore, initial analysis of several Eμ-D1T286A/ATM-/- murine
tumors revealed clonal chromosomal translocations, in contrast to gross aneuploidy
previously observed in Eμ-D1T286A-expressing lymphomas (Aggarwal et al., 2007).
This phenotype also contrasts that of ATM-/- mice, where tumors arise in CD4+CD8+
immature T-cells coincident with V(D)J recombination; as a result, these tumors typically
harbor chromosome 14 translocations involving the T-cell receptor / locus, with
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t(12;14) as a frequently observed alteration (Liyanage et al., 2000). The fact that
preliminary Eμ-D1T286A/ATM-/- cytogenetic phenotype differs from Eμ-D1T286A or
ATM-/- tumors suggests potential synergy between nuclear cyclin D1 function and
impaired checkpoint response in tumor initiation.
The few Eμ-D1T286A/ATM-/- tumors analyzed in preliminary cytogenetic
experiments exhibit clonal translocations commonly involving chromosome 15. The
well-characterized t(12;15) translocation, for example, juxtaposes the c-Myc and
immunoglobulin heavy-chain (IgH) loci, promoting aberrant c-Myc overexpression
(Ramiro et al., 2004). While mature B-lymphocytes are prone to DSBs in Ig loci during
class switch recombination (CSR) and somatic hypermutation (SHM), two processes
necessary for antibody diversification (Robbiani et al., 2008), we observed t(12;15)
translocations in both B- and T-cells suggesting that an alternative mechanism underlies
DSB induction and translocations within these regions. Interestingly, the murine c-Myc
locus resides on chromosome 15, and an origin of replication was mapped approximately
1kb upstream of c-Myc, conserved in human, mouse, and xenopus (Ghosh et al., 2006;
Girard-Reydet et al., 2004). Thus, it is possible that nuclear cyclin D1-dependent CUL4
repression/CDT1 stabilization promotes DNA re-replication in developing B- and T-cells,
and frequent replication fork collision/collapse leads to DSB induction. In the absence of
ATM, such breaks would not be efficiently sensed and repaired, resulting in
chromosomal translocations.
While my proposed mechanism could occur theoretically at any replication origin,
productive chromosome alterations that facilitate loss of tumor suppressor proteins or
activation of oncogenes should be clonally selected for tumor growth. Preliminary
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evidence in support of this model is that clonal translocations typically involve
chromosome 15, potentially leading to c-Myc deregulation. Since clonal t(12;15) is
present in Eμ-D1T286A/ATM-/- tumors, we also considered whether DNA re-replication
could promote breaks downstream of the IgH locus in an AID (Activation-induced
cytidine deaminase)-independent manner, since AID is primarily expressed in germinal
center B-cells and is involved in CSR and SHM processes during B-cell development.
Interestingly, an origin was mapped between the murine 3’IgH regulatory region and the
downstream gene, Crip; further analysis revealed that sequences downstream of this
region are replicated bi-directionally, while upstream sequences including IgH C, D, and
J segments replicate in a single direction (Norio et al., 2005; Zhou et al., 2002). Bidirectional fork movement in the context of DNA re-replication could generate
significant DNA damage, permitting chromosome translocations involving this region as
well.
To formally examine these hypothesis, future work is focused on demonstrating
enrichment of origin binding proteins (CDC45, MCM3, MCM7) within putative
replication origins when cyclin D1T286A is expressed in mouse and human cell culture
systems. This simplified experimental system should permit analysis of a single S-phase
in the presence of acutely overexpressed cyclin D1T286A, and origin binding protein
enrichment at c-Myc has been previously established (Ghosh et al., 2006), validating this
approach. I will also examine origin binding protein enrichment at the c-Myc locus in
vivo by assessing CDC45, MCM, and ORC binding to this region by ChIP in nontransgenic control and Eμ-D1T286A-expressing splenocytes. Together, these descriptive
and mechanistic studies are of significant importance with regard to human cancer, as
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cyclin D1 deregulation is a hallmark of MCL, and t(11;14) translocations responsible for
ectopic cyclin D1 expression frequently disrupt the ATM locus on chromosome 11 as
well. Future work will include allograft transplant of Eμ-D1T286A or EμD1T286A/ATM-/- tumor cells into recipient mice, followed by treatment with various
chemotherapeutic regimens to determine how these genetic alterations influence
sensitivity to conventional DNA damaging chemotherapy, thereby elucidating effective
regimens for tumor regression.

Concluding remarks.
Previous and current studies characterizing cyclin D1T286A transgenic mice or
Fbx4-deficient mice invoke a model where impaired cyclin D1 phosphorylation or Fbx4
ligase inactivation facilitates accumulation of active, nuclear cyclin D1/CDK4 kinase
following the G1/S transition. In S-phase, cyclin D1/CDK4 phosphorylates MEP50,
thereby triggering increased PRMT5-dependent methyltransferase activity, subsequent
CUL4 repression, and CDT1 stabilization, ultimately driving DNA re-replication. Initial
DNA damage checkpoint responses counter cell transformation; however, alterations in
the p53 tumor suppressor pathway ultimately permit aneuploidy and neoplasia. Similarly,
in the absence of checkpoint responders such as ATM, nuclear cyclin D1/CDK4 drives
DNA re-replication; however, an impaired checkpoint response to DNA damage likely
facilitates chromosomal translocations which could be clonally selected based on growth
or survival advantages for transformed cells (Figure 5.4).
Collectively, the analyses presented in this thesis highlight the functional
significance of cyclin D1 deregulation and provide novel insight into oncogenic functions
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of nuclear cyclin D1/CDK4 kinase. Ultimately, elucidating mechanisms of cyclin D1driven genomic instability will facilitate development of novel detection and therapeutic
approaches for diagnosing and treating cyclin D1 overexpressing cancers. Considering
these findings, could cyclin D1 overexpression or inactivating mutations in Fbx4 serve as
biomarkers for cancer therapy? Preliminary results suggest yes. Inactivating Fbx4
mutations in esophageal carcinoma correlate with an intense histone arginine dimethylation signature by IHC; this mark could, in fact, serve as a biomarker for
deregulated cyclin D1/CDK4 function in human tumors. Analysis of a broad range of
tumors known to harbor alterations in Fbx4 or constitutively nuclear cyclin D1 will
further validate this IHC approach.
Furthermore, mouse models revealed that cyclin D1/CDK4 contributes to
neoplasia at least in part through perturbations in DNA replication and loss of genomic
integrity; exploiting this phenotype is an attractive therapeutic strategy. For example, one
scenario might be to take advantage of the fact that tumors harboring mutations in cyclin
D1 or Fbx4 have a compromised DNA damage checkpoint. In theory, treatment of
normal cells with chemotherapeutic agents that generate DNA crosslinks should trigger
an intra S-phase checkpoint, thereby providing an opportunity for repair. Expression of
stabilized cyclin D1 should promote maintenance of CDT1 and MCM complexes on
chromatin, promoting continued origin firing without repair, ultimately resulting in
mitotic catastrophe. Further work is required to investigate how alterations in cyclin D1
proteolysis might influence cellular responses to DNA damaging therapeutics in vivo.
Alternatively, drugs that directly target CDKs have been developed, and various
CDK inhibitors are currently in clinical trials. The small molecule CDK4/6 inhibitor PD
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0332991 is highly specific for these CDKs and elicits cell cycle arrest in vitro and in
xenograft models in vivo, as evidenced by reduced Rb phosphorylation, downregulation
of E2F target genes, and reduced Ki-67 staining, an IHC marker of proliferation (Fry et
al., 2004). Importantly, the mode of action of PD 0332991 is cytostatic, leading to cell
cycle arrest, but not apoptosis, suggesting low toxicity for normal cells; however, alone,
it is insufficient to elicit tumor killing, highlighting the requirement for combination
therapy. In addition to direct CDK inhibition, modulation of signaling responses
downstream of CDK-mediated phosphorylation also has therapeutic promise. For
instance, recent identification of MEP50 as a novel CDK4 substrate and subsequent data
demonstrating that MEP50 phosphorylation triggers increased PRMT5 enzymatic activity
suggest that targeting the PRMT5 methyltransferase may be an effective therapeutic
approach. Preliminary evidence revealed that treatment with commercially available
PRMT inhibitors sensitizes transformed cyclin D1T286A lymphoma cells to apoptosis in
vitro. Analysis of these “proof-of-concept” inhibitors in mice, as well as development of
potent, specific small molecule inhibitors of PRMT5 is of great clinical relevance.
Phosphorylation-dependent nuclear export and subsequent degradation of cyclin
D1 is essential to maintain cellular homeostasis. Disruption of this regulatory pathway
has been extensively shown to promote neoplastic transformation; however, the precise
mechanism of this event has been elusive. Significantly, recent work revealed that
nuclear accumulation of active cyclin D1/CDK4 complexes generates genomic instability
through PRMT5-dependent transcriptional repression, CDT1 stabilization, and DNA rereplication. Furthermore, Fbx4 functions as a haploinsufficient tumor suppressor in vivo,
and mutations targeting SCFFbx4 in human cancer implicate ligase function in cyclin D1
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overexpression and subsequent nuclear accumulation of active cyclin D1/CDK4 kinase.
Importantly, GSK3 functions as the master switch, turning on cyclin D1 destruction at
the G1/S transition by regulating both ligase activation and cyclin D1 phosphorylation.
Given the phenotypic outcome of accumulated nuclear cyclin D1/CDK4, further
mechanistic investigation is required for development of novel therapeutic strategies to
promote tumor cell death in cancers overexpressing cyclin D1.
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CHAPTER VI:
MATERIALS AND METHODS
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Chapter 2
Cell Culture Conditions. NIH 3T3, MDA-MB 231, MCF7, U20S, ATRflox/- CET
immortalized ear fibroblasts, and 293T cells were maintained in complete DMEM media
containing glutamine, 1% penicillin/streptomycin, and 10% FBS. (MDA-MB 231 and
MCF7 cells were also supplemented with 10μg/mL insulin). KYSE 520 and TE3/TE7
cells were maintained in RPMI media containing glutamine, antibiotics, and 10% FBS.
NIH 3T3 cells stably expressing FLAG-D1, FLAG-D1T286A, FLAG-D1290-95A, B
crystallin shRNA, and Fbx4 shRNA have been previously described (Benzeno and Diehl,
2004; Diehl et al., 1997; Lin et al., 2006). For synchronization, NIH 3T3 cells and their
derivatives were cultured in media containing 0.1% fetal bovine serum for 24 hours
followed by addition of FBS for 15 hours for a synchronous S-phase population as
determined by FACS. For transient plasmid expression, cells were transfected using
Lipofectamine/Plus (Invitrogen).

Cell treatments and inhibitors. Acute ATR deletion was achieved by treating cells with
200nM 4-OH tamoxifen for 24h. Genotoxic stress was induced by -irradiation using a
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Cs Source (MS Nordion Gammacell 40 Exactor), 2mM HU, 10 or 20g/mL

bleomycin, or 5M aphidicolin. For proteasome inhibition experiments, cells were
treated with 10mM MG132 (Calbiochem) and 2mM HU for 4 hours. The following
small-molecule inhibitors were used according to manufacturer’s recommendation:
GSK3 inhibitors LiCl (Sigma) and SB216763 (Calbiochem), and p38 inhibitor
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SB203580 (Calbiochem); cells were pre-treated with inhibitors for 30 minutes prior to
DNA damage induction. For ATM inhibition, cells were pre-treated with KU-55933
(Sigma) for 30 minutes. For Chk1 or Chk2 inhibition, cells were pre-treated with
SB218078 (Calbiochem) or Chk2 inhibitor II (Sigma) for 30 minutes, followed by DNA
damage. The pJ3M-kdGSK3 construct was described previously (Diehl et al., 1998).
Chromatin fractionation was described previously (Gladden and Diehl, 2003).

Cell Cycle Analysis. NIH3T3 cells stably expressing cyclin D1 or D1T286A were
treated with CPT for 24 or 48 hours. Cells were washed with PBS, fixed with ethanol,
and stained with propidium iodide for 30 minutes, prior to FACS analysis. Cell cycle
profiles based on DNA content were established using FlowJo software, and the sub-G1
population of cells served as a readout for apoptotic cells following CPT treatment in
three independent experiments.

Immunoblotting. Cells were lysed in Tween 20 buffer containing protease and
phosphatase inhibitors (50mM HEPES (pH 8.0), 150mM NaCl, 2.5mM EGTA, 1mM
EDTA, 0.1% Tween 20, 1mM DTT, 0.1mM PMSF, 20U/mL aprotinin, 10mM glycerophosphate, 5μg/mL leupeptin, and 1mM NaF). M2 Agarose beads were utilized to
precipitate Flag-tagged protein. Antibodies used for direct western include cyclin D1-7213G, phospho-T286 rabbit polyclonal antibody, cyclin D2, cyclin E, CDK4, myc 9E10
(Santa Cruz), -H2AX, phospho-p38, Chk1, phospho-p53 (Ser 15), phospho-ATM (Cell
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Signaling), ATM, ATR (Serotec), Chk2, GSK3 (BD Transduction Labs), -actin
(AC15, Sigma), B Crystallin (SPA 223, Stressgen), and Fbx4 (Rockland).

In vitro Kinase Assay. Equal concentration of endogenous GSK3 was precipitated from
NIH3T3 cells that were untreated or subjected to IR using protein A-sepharose beads in
GSK3 immunoprecipitation buffer: 50mM Tris-HCl pH 7.5, 1mM EDTA, 1mM EGTA,
10% TritonX-100, 0.27M sucrose, 1mM DTT and protease/phosphatase inhibitors.
GSK3-bound beads were washed with kinase buffer: 20mM Tris-HCl, 40mM MgCl2,
2.5mM EGTA, 1mM DTT, protease/phosphatase inhibitors, and 20μM ATP. Reactions
were carried out in the presence of 32P-ATP for 20 minutes at 30°C, resolved by SDSPAGE and transferred to a nitrocellulose membrane. Immunoblot for GSK3 indicated
equal precipitation of kinase.

Metaphase Spreads. Splenocytes were isolated from transgenic E-D1T286A or nontransgenic control mouse spleens and cultured for 48 hours in RPMI medium
supplemented with L-Glutamine, LPS, -Mercaptoethanol, Concavalin A, and FBS.
Cultures were treated with 100μM mitomycin-C (MMC) for 24h to induce damage. For
HU experiments, cultures were treated for 2 hours with 2mM HU, washed, and resuspended in fresh media. Cells were arrested in metaphase by treatment with colcemid
(Gibco) for 2 hours. Cells were treated with hypotonic KCl solution and fixed with
methanol-acetic acid. Metaphase spreads were dropped, permitted to dry overnight, then
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stained with Giemsa (Sigma). The average number of chromatid breaks per cell was
scored in 16 metaphase spreads following HU treatment or 25 total spreads for MMC
treatment. NIH3T3 cells expressing vector control, Fbx4shRNA, or cyclin D1T286A
were synchronized by serum starvation, treated with 2mM HU for 3 hours during Sphase, followed by 4 hours of 0.5μM nocodazole treatment to arrest cells in metaphase.
Metaphase spreads were prepared as described for splenocytes, and chromatid breaks in
20 metaphases for each treatment were scored in a blind fashion.

RDS Assays. Cells were synchronized by serum starvation for 24 hours in the presence
of 20nCi [14C]thymidine (Amersham). Cells were subsequently washed with PBS, and
DMEM containing 10% serum was added to trigger S-phase entry. S-phase populations
were exposed to 10 Gy IR as indicated and a recovery period at 37ºC for 30 minutes.
Cells were then pulsed with 20Ci [3H]thymidine (PerkinElmer) for 2 hours, and total
DNA was isolated by high salt extraction. Equal concentrations of purified DNA were
subjected to scintillation counting, and DNA synthesis was expressed as the ratio of
[3H]/[14C] incorporation, normalized to non-irradiated cells.

shRNA/siRNA. Luciferase control and Chk2-specific siRNAs (Dharmacon smartpool)
were kindly provided by Dr. Roger Greenberg, University of Pennsylvania. ATR-specific
siRNA smartpool was purchased from Dharmacon. siRNAs were transfected into U20S
cells using HiPerfect (Qiagen). Cells were irradiated 60h post siRNA transfection and
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harvested for western blotting. For Chk1 shRNA experiments, scramble control or Chk1
shRNA lentivirus were used to infect NIH3T3 cells. 72 hours post infection, cells were
plated and synchronized by serum starvation. Cells were released into complete media,
and after 15 hours, cells were treated with HU to induce replication stress in S-phase.

Statistical Analysis. Error bars indicate represent ± standard deviation. The Student’s ttest was used to compare groups in RDS assays, metaphase spread analysis, and
sensitivity to CPT assays. Western blotting quantification was performed by
densitometric analysis. Error bars indicate represent ± standard deviation of the
densitometry of 3 independent experiments.

Chapter 3
Targeting Vector Construction and Generation of Fbx4-/- Mice. The engineered
construct targeting murine Fbx4 exon 2 was developed by Vega Biolab (Philadelphia,
PA). The targeting vector was electroporated into ES cells, and clones harboring a
correctly targeted allele with a normal karyotype were injected in B6 blastocysts by the
University of Pennsylvania core facility for generation of chimeric mice with germline
transmission; these mice were intercrossed with EIIa-Cre transgenic mice to generate
Fbx4 heterozygous progeny. Genotypes were verified by PCR using tail DNA (Extraction
and PCR performed with Extract-N-Amp Tissue PCR Kit, Sigma-Aldrich). The
following PCR primer sequences were used for genotyping:
1loxP-F, 5’-GGCAGAGCTTGAGTTTGCAACATTTCAGGTG-3’;
3loxP-R, 5’-TCCTGATCTTTGGAAATTCTTCCTCTGAGT-3’.
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Aged mice were examined daily for signs of distress or palpable tumor mass according to
IACUC guidelines, and tumor-free survival was assessed by Kaplan-Meier analysis.

Southern Hybridization. 5’ and 3’ probes in the genomic region flanking Fbx4 exon 1-3
(site of homologous recombination, see Figure 3.1) were generated.

The 5’ probe

generates a band of 15kb for normal Fbx4 locus, and a 10kb band for an allele that has
undergone homologous recombination.

Histology/Immunohistochemistry. Tissues were fixed in 10% buffered formalin
overnight,

followed

by

dehydration

in

a

series

of

ethanol

and

paraffin

embedding/sectioning. Antibodies utilized for IHC staining were purified cyclin D1 (7213G, Santa Cruz) and Ki-67 (Novocastra).

MEFs and Cell Culture. Mouse embryos extracted at day 14 of gestation were
maintained on a 3T9 passage protocol (9x105 cells passaged every three days on 60mm
plates), cultured in DMEM containing 10% fetal bovine serum, 2mM glutamine, 0.1mM
non-essential amino acids, 55μM -mercaptoethanol, and 10μg/mL gentamicin. For
growth curves, 1x105 cells were plated on 35mm dishes in duplicate and counted every
24 hours by using a hemocytometer. Cell counts were also verified using the Countess
Automated Cell Counter (Invitrogen). Primary MEFs were immortalized by lentiviralmediated infection with p19Arf shRNA vector, generously provided by Dr. Eric Brown’s
laboratory, University of Pennsylvania. Immortalized cells and NIH 3T3 fibroblasts were
cultured in complete DMEM containing 10% fetal bovine serum, glutamine, and 1%
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penicillin/streptomycin. Cell synchronization was achieved by serum starvation for 36-48
hours, followed by serum stimulation to allow cell cycle entry.

Western analysis. Whole tissues and cultured cells were lysed in Tween 20 buffer
containing 50mM HEPES (pH 8.0), 150mM NaCl, 2.5mM EGTA, 1mM EDTA, 0.1%
Tween 20, and protease/phosphatase inhibitors (1mM PMSF, 20U/mL aprotinin, 5mg/mL
leupeptin, 1mM DTT, 0.4mM NaF, and 10mM -glycerophosphate). Whole tissues were
homogenized in Tween 20 buffer with inhibitors, and tissue and cell culture lysates were
sonicated prior to lysate clearing by centrifugation at 4°C for 30 minutes. Lysate protein
concentration was determined by BCA assay, and proteins were resolved by SDS-PAGE,
transferred to nitrocellulose membranes, and subjected to immunoblotting. Antibodies
utilized include Fbx4 rabbit polyclonal antibodies (YenZym, Rockland), cyclin D1 mouse
monoclonal D1-72-13G, H4R3 (Abcam), H2AX (Cell Signaling), p53 mouse
monoclonal pab421, p21 and cyclin A (Santa Cruz), and -Actin (Sigma).

Immunofluorescence. Primary MEFs were plated at optimal densities on glass
coverslips. For cyclin D1 localization, passage 3 primary MEFs were grown to 70-80%
density, then fixed in 1:1 methanol:acetone for 10 minutes at -20°C. Coverslips were
dried then rehydrated with PBS, blocked with 10% fetal calf serum in PBS for 30
minutes, then incubated with cyclin D1-72-13G primary antibody for 1 hour. Coverslips
were washed 3x with PBS, followed by incubation with anti-mouse Alexa Fluor 546
secondary antibody for 30 minutes. Coverslips were washed 3x with PBS, dried by 70%
and 100% ethanol washes and mounted with Vectashield mounting media containing
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DAPI (Vector Laboratories). For H2AX foci visualization, passage 3 cells maintained
under atmospheric (21%) oxygen conditions or physiological (3%) oxygen tension were
plated on glass coverslips at a density of 1x105 cells/well of a 6-well plate and cultured
for 24 hours. Cells were fixed and blocked as described above, followed by incubation
with H2AX antibodies for 2 hours. Coverslips were washed 3x with PBS, then incubated
with anti-rabbit Alexa Fluor 488 secondary antibody for 30 minutes. Coverslips were
washed and mounted as described above, and visualized with a Nikon Eclipse 80i
fluorescent microscope.

Metaphase Spreads. Immortalized MEFs were synchronized by serum starvation,
followed by serum stimulation to allow progression into S-phase. Cells in mid-S-phase
were pulsed with HU for 2 hours, followed by HU washout and incubation in complete
DMEM media. Cells were arrested in metaphase by treatment with colcemid for 2 hours,
harvested, treated with hypotonic KCl solution and fixed with methanol-acetic acid.
Metaphase spreads were dropped onto glass slides and permitted to dry, followed by
Giemsa staining (Sigma). The average number of chromatid breaks per cell was scored in
two independent biological replicate cell lines for each genotype.

In vivo Ubiquitylation. Immortalized MEFs were synchronized by serum starvation and
stimulated for 15 hours to enter early S-phase. Cells were treated for 3 hours with 10μM
MG-132 (Calbiochem) for proteasome inhibition and harvested in Tween 20 buffer
containing proteasome and phosphatase inhibitors, 1mM DTT, 10mM N-ethylmaleimide
(NEM), and 20μM MG-132, followed by immunoprecipitation with cyclin D1 72-13G
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antibody as described above. IP samples were resolved by SDS-PAGE on 10% polyacrylamide gels and immunoblotted with phospho-cyclin D1 T286 antibodies and total
cyclin D1 to visualize ubiquitylated cyclin D1 laddering.

In vitro Ubiquitylation. NIH 3T3 cells were synchronized by serum starvation, followed
by serum stimulation to enter S-phase. Cells were either untreated or subjected to 10Gy
IR, followed by 30 minutes of recovery. Cells were then harvested in Tween 20 buffer,
and 1mg of total protein was immunoprecipitated with Fbx4 antibodies and protein A
sepharose beads for 4 hours at 4°C. Fbx4-containing endogenous SCF complexes were
washed 4x with Tween-20 buffer, then 3x with kinase buffer (20mM Tris, 40mM MgCl2,
2.5mM EGTA). Beads containing SCFFbx4 complexes were then mixed with Sf9-produced
purified cyclin D1 substrate, ATP, ubiquitin, E1, E2, MG-132, ubiquitin aldehyde,
okadaic acid, energy regeneration buffer (20x: 10mM ATP, 20mM Hepes pH 7.4, 10mM
MgOAc, 300mM creatine phosphate, 0.5mg/mL creatine phosphokinase) and kinase
buffer to a final volume of 50μL. Reactions were carried out at 37°C for 30 minutes,
followed by SDS-PAGE for visualization of ubiquitylated cyclin D1 by western blot.

In vitro Transformation Assays. Primary passage 3 MEFs were transduced with pBabePuro (empty vector) or pBabe-RasV12 retrovirus. 24 hours post infection, cells were
trypsinized and re-plated at a density of 1.5x105 cells/35mm plate in duplicate. Cells were
cultured in DMEM containing 5% serum, with media changed every 2 days for 21 days,
followed by giemsa stain to visualize foci. For spontaneous transformation of
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p19shRNA-immortalized MEFs, early passage cells were plated at a density of
1.5x105/35mm plate and cultured as described above.

Statistical Analysis. Prism GraphPad Software was utilized for generating Kaplan-Meier
mouse tumor free survival plots and statistical analysis of survival and tumor onset (log
rank test). All other statistical analyses utilized a two-tailed student’s t-test, with p-values
less than 0.05 indicating statistical significance. Error bars represent the mean ± the
standard deviation.

Chapter 4
Cell Culture, Transfections and Plasmids. Cell culture conditions and transfections
were performed as previously noted (Aggarwal et al., 2007). The human PRMT5 Myctagged vector was generated by PCR using primers designed for directional cloning into
pCS2-MT plasmid (in frame with six Myc epitope tags at the N terminus of PRMT5),
using PRMT5 cDNA (Open Biosystems) as the template. Human GST-tagged MEP50
vector was generated by PCR of human MEP50 with primers designed for directional
cloning into pGEX-4T-1 plasmid (in frame with GST tag at the N terminus of MEP50),
using pOTB7-MEP50 (Open Biosystems) as the template. Human MEP50 Myc-tagged
vector was generated by PCR of human MEP50 with primers designed for directional
cloning into pcDNA3 plasmid (in frame with 1X Myc tag at the N terminus of MEP50).
Site directed mutagenesis was performed using QuikChange Site-Directed Mutagenesis
Kit (Stratagene). All clones were sequenced in their entirety.
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Chromatin

Immunoprecipitation

Assay.

Cells

were

cross-linked

in

0.75%

formaldehyde for 10 min and quenched with 0.18mM glycine for 5 min. Cells were
harvested in cell lysis buffer (50mM HEPES, pH 7.5, 140mM NaCl, 1mM EDTA pH8.0,
1.0% Triton-X-100, 0.1% SDS, 0.1% deoxycholate, fresh protease inhibitors) and
chromatin sheared to an average size of 350-600 bp by sonication (3x10min cycles of
30x30 sec each) at constant output (high setting, Bioruptor). Sonicated DNA was diluted
3-fold in dilution buffer (20mM Tris-HCl pH 8.0, 2mM EDTA pH 8.0, 1% Triton X-100,
150mM NaCl, protease inhibitors) and pre-cleared with protein A plus-agarose
(Millipore). Lysates were rotated at 4°C overnight with 5g of polyclonal antibodies
specific for H4R3 (Abcam) or H3R8 anti-sera as described below, PRMT5 (Abcam), M2
monoclonal (Sigma), Brg1 (Santa Cruz) or normal rabbit IgG (Cell Signaling). After
washing, complexes were eluted in 130l of Elution buffer (1% SDS + 100mM
NaHCO3), followed by addition of 100g of proteinase K at 65°C overnight for crosslink reversal. The DNA was purified by phenol-chloroform extraction and precipitated
DNA was analyzed by qPCR. CUL4A and CUL4B primers are described in Figure 4.3.

Immunoprecipitation and Immunoblot Analysis. Cells were harvested in Tween 20
buffer (50mM HEPES (pH 8.0), 150mM NaCl, 2.5mM EGTA, 1mM EDTA, 0.1%
Tween 20, protease, and phosphatase inhibitors (1mM PMSF, 20 U/ml aprotinin, 5mg/ml
leupeptin, 1mM DTT, 0.4mM NaF, and 10mM -glycerophosphate), and protein
concentration of samples was determined by BCA assay. Cyclin D1, PRMT5 and MEP50
were precipitated using M2 anti-flag agarose (to recognize flag-tagged proteins, SigmaAldrich), PRMT5 rabbit polyclonal antibody (Abcam) or c-myc (9E10) and MEP50
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rabbit polyclonal antibody (Bethyl Lab. Inc), respectively. Proteins were resolved by
SDS-PAGE, transferred to nitrocellulose membranes, and analyzed by immunoblotting.
Antibodies used in these studies were as follows: Fbx4 rabbit polyclonal antibody
(Rockland), cyclin D1 mouse monoclonal D1-72-13G, cyclin D1 mouse anti-human
(AB3, Calbiochem); -actin (Sigma-Aldrich); CUL4A rabbit polyclonal (Bethyl Lab.
Inc); CUL4B rabbit polyclonal (ProteinTech Group Inc); pSP/TP mouse monoclonal
(16B4, Biomol); CDK4 (C-22 or H-22), Cdt1, Brg1, RB, PRMT5 mouse monoclonal,
PRMT2, mSin3a (Santa Cruz); H4R3 rabbit polyclonal-ChIP grade, H3K4 rabbit
polyclonal, Histone H3 rabbit polyclonal, PRMT1 and PRMT7, Histone H4 rabbit
polyclonal (Abcam). Anti-H3R8 (corresponding to symmetric di-methylated R8 of
human histone H3) antibody was generated by immunizing rabbits with peptide
containing modified histone H3 (YenZym Antibodies, LLC) followed by affinity
purification. Antibody binding was visualized by chemiluminescence (Perkin Elmer).

Immunohistochemistry. Human esophageal tumors harboring Fbx4 mutations and
normal esophageal tissue were obtained with informed consent and with Institutional
Review Board approval from the University of Pennsylvania (IRB #803902), Fox Chase
Cancer Center (IRB #98-53), and University of Fukui, Japan (IRB #H190228-155).
Tissue was fixed in 10% buffered formalin and dehydrated, paraffin embedded and
sectioned. Tissue sections were immunostained using rabbit polyclonal H4R3 (Abcam) at
1:500 dilution as the primary antibody.
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In vitro kinase assay and in vitro methyltransferase assay. Purified GST-MEP50 wild
type, GST-T5A, S176A, S264A, S306A mutants and GST-RB were used as substrates
for in vitro kinase reactions (Matsushime et al., 1994). Cyclin D1/CDK4 kinase
complexes were purified from Sf9 cells. For assessment of PRMT5 methyltransferase
activity, PRMT5 complexes were collected from the indicated sources by
immunoprecipitation. Beads were washed in Tween 20 buffer followed by
methyltransferase buffer (15mM HEPES (pH7.9), 100mM KCl, 5mM MgCl2, 20%
Glycerol, 1mM EDTA, 0.25mM DTT and 0.5mM PMSF). The methylation reaction
included PRMT5 immune complexes on beads, 1μg recombinant Histone H4 (NEB), and
2.75μCi S-adenosyl-L-(methyl-3H)methionine (Amersham Pharmacia) in a total volume
of 25μl for 1.5 hours at 30oC. The reaction mixture was resolved on SDS-polyacrylamide
gel, and modified histone H4 was detected by fluorography.

For coupled kinase

assay/methyltransferase assays, cyclin/CDK complexes were purified from Sf9 cells and
mixed with purified recombinant PRMT5/MEP50 (produced in Sf9 cells, BPS
Bioscience) or PRMT5 precipitated from HeLa cells immobilized on beads. In vitro
kinase assays were performed for 30 minutes at 30°C in kinase buffer. PRMT5containing beads were washed into methyltransferase buffer, followed by in vitro
methylation reaction for 2 hours at 30°C with 2g H4 substrate and 2.75Ci 3H-SAM.
Methyl-H4 was visualized by fluorography/scintillation counting for 3H incorporation.

Foci Formation. Low passage NIH3T3 cells were transfected with control or murine
PRMT5 siRNA (Dharmacon) using HiPerfect (Qiagen). 24 hours post siRNA delivery,
cells were transfected with 2ug of the indicated plasmids (pBabe Ras V12 or pBabe
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cyclin D1T286A) or empty vector (pBabe puro) using Lipofectamine/Plus Reagent
(Invitrogen). Transfected cells were counted after 48 hours, and 2x105 cells were plated
in duplicate on 35mm plates in DMEM containing 5% FBS. Cells were re-fed with
DMEM plus 5% FBS every 2 days for 14 days, followed by staining with Giemsa to
visualize foci formation. Foci were counted for duplicate plates and error bars represent ±
standard deviation and * indicates p-value < 0.05, as determined by student’s t-test. For
MEP50 overexpression assays, NIH3T3 cells were transfected with 2ug of wild type
MEP50 or phosphorylation-deficient MEP50 mutant T5A or S264A, along with empty
vector or Ras V12 and cyclin D1T286A constructs as indicated. Cells were seeded and
foci formation was analyzed as described above.

Real time quantitative PCR analysis of gene expression. RNA isolation was performed
using standard protocols. DNA fragments were generated by reverse transcriptase PCR
(RT-PCR; SuperscriptTM, Invitrogen). Mixed primer/probe sets for human CUL4A/B and
18S rRNA were used to measure the levels of these transcripts using the Applied
Biosystems 7900HT sequence detection system according to the manufacturer's
instructions. Primers used for detection of human CUL4A and CUL4B were described
previously (Aggarwal et al., 2007).

siRNA and Methyltransferase Inhibitor experiments. siGENOME SMARTpool
targeting PRMT5 and MEP50 or control siRNA were purchased from Dharmacon. HeLa
cells were treated with indicated siRNA or methyltransferase inhibitors, MTA (Sigma) or
AMI-1 (Calbiochem), for 24 hours followed by transfection and synchronization of cells
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in G1 and S-phases. For targeting 3’ UTR region of human MEP50, siRNA (5’
CUCCUUACCAUUAAACUGA 3’) was designed and purchased from Sigma.
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